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The use of targeted cancer therapies in combination with conventional chemotherapeutic agents and/or radiation treatment has
increased overall survival of cancer patients. However, longer survival is accompanied by increased incidence of comorbidities
due, in part, to drug side eﬀects and toxicities. It is well accepted that inﬂammation and tumorigenesis are linked. Because
peroxisomeproliferator-activatedreceptor(PPAR)-γ agonistsarepotentmediatorsofanti-inﬂammatoryresponses,itwasalogical
extension to examine the role of PPARγ agonists in the treatment and prevention of cancer. This paper has two objectives: ﬁrst to
highlight the potential uses for PPARγ agonists in anticancer therapy with special emphasis on their role when used as adjuvant
or combined therapy in the treatment of hematological malignancies found in the vasculature, marrow, and eyes, and second,
to review the potential role PPARγ and/or its ligands may have in modulating cancer-associated angiogenesis and tumor-stromal
microenvironment crosstalk in bone marrow.
1.Introduction
Peroxisome proliferator activated receptors (PPARs) are a
subfamily of the larger nuclear hormone receptor super-
family of transcription factors [1, 2]. Three distinct but
closely related isoforms designated PPARα,P P A R β/δ,a n d
PPARγ make up the family. PPARγ functions are further
delineated by two isoforms PPARγ1a n dP P A R γ2, which
arise due to alternative promoter usage accompanied by
alternative splicing and/or polyadenylation of the primary
transcript (recently reviewed in [3]). PPARs are best known
for their roles in lipid homeostasis and energy metabolism
including cholesterol and triglyceride turnover [4], obesity
[5], metabolic syndrome [6–9], and diabetes [5, 10, 11];
however, since their discovery, the PPARs and/or PPAR
agonists have been implicated in a broader spectrum of
biological processes playing protective and homeostatic roles
such as promoting wound healing [12, 13] and, for the most
part, countering the eﬀects of aging [14], cardiovascular
disease [15, 16], inﬂammation and immune responses [17–
19], thrombosis and hemostasis [7, 8, 17–21], pathological
angiogenesis [22–32], and cancer [24, 25, 31–41].
A number of naturally occurring ligands activate PPARγ
(Table 1), such as unsaturated fatty acids and eicosanoids
[42], 15-deoxy-Δ-12-14-prostaglandin J2 (15d-PGJ2), and
components of oxidized low density lipoproteins (LDLs)
[43]. The aﬃnity of PPARγ for many of the endogenous
ligands is low and, in some cases the physiological relevance2 PPAR Research
Table 1: PPAR-γ ligands.
Natural ligands Ref.
lysophosphatidic acid [349]
nitrolinoleic acid [350]
9-hydroxyoctadecadienoic acid [351, 352]
13-hydroxyoctadecadienoic acid [351, 352]
15-hydroxyeicosatetraenoic acid [353]
prostaglandin D2 [351, 353–357]
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)[ 351, 353–357]
Synthetic Ligands Ref
Thiazolidinedione family (TZDs) [18, 44, 313, 353, 354, 358, 359]
ciglitazone
pioglitazone
rosiglitazone
troglitazone
TZD 18
Nonsteroidal anti-inﬂammatory drugs [353, 360, 361]
indomethacin
ibuprofen
ﬂufenamic acid
fenoprofen
L-tyrosine-based [351, 352]
GW-7845
GW-1929
diindolylmethane analogs [351, 362]
triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) [46, 351]
CDDO C-28 methyl ester derivative (CDDO-Me) [214, 363, 364]
CDCO C-28 imidazole (CDDO-Im) [50]
1,1-bis[3 -(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane (DIM #34), [365]
of the ligand needs to be determined. However, it is well
accepted that 15d-PGJ2 is the most potent endogenous
ligand for PPARγ. The thiazolidinediones (TZDs) are a
class of synthetic ligands with high aﬃnity for PPARγ that
are used for their antidiabetic eﬀects to sensitize cells to
insulin [44]. Nonsteroidal anti-inﬂammatory drugs such as
ibuprofen and indomethacin are low aﬃnity PPARγ ligands
[45]. Furthermore, the synthetic triterpenoid, 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO), and derivatives
are high aﬃnity ligands for PPARγ [46]( Table 1).
Two overarching principles should be kept in mind when
weighing the plethora of therapeutic beneﬁts touted for
PPARγ agonists. First, PPARγ agonists evoke both PPARγ-
dependent and PPARγ-independent eﬀects, thus therapeutic
beneﬁts ascribed to certain PPARγ ligands do not necessarily
require interaction with the PPARγ ligand binding domain.
Although PPARγ-independent eﬀects induced by 15d-PGJ2
and CDDO are due in part to the electrophilic nature of
these ligands [47–50], PPARγ-independent eﬀects induced
by TZDs are through a number of signaling pathways
including inhibition of Bcl-2/Bcl-xL function, proteasomal
degradation of cell cycle- and apoptosis-regulatory proteins,
and transcriptional repression [51]. Second, PPARγ agonists
have been shown to have paradoxical physiological eﬀects,
likely due to tissue-speciﬁc and/or context-dependent regu-
latory signaling events.
Recently, we reviewed the role of PPARγ and its ligands
in the treatment of hematological malignancies, which is
summarized in Tables 1 and 2 [3]. The purpose of this
paper is twofold: ﬁrst to highlight the potential uses for
PPARγ agonists in anticancer therapy with special emphasis
on their role when used as adjuvant or combined therapy in
the treatment of hematological malignancies, and second, to
reviewthepotentialrolePPARγ andPPARγ ligandsmayhave
in modulating cancer-associated angiogenesis and tumor-
stromal microenvironment crosstalk in bone marrow—two
pathophysiological events associated with most all types of
cancer including hematological malignancies.PPAR Research 3
Table 2: PPARγ and PPARγ ligands as potential therapy for hematological malignancies.
Hematological
malignancy/cell line PPARγ agonist Comments Ref
HL-60 troglitazone Inhibited cell proliferation by G1 arrest;
induced diﬀerentiation to monocytes
[366]
HL-60 15d-PGJ2, troglitazone Inhibited cell proliferation; induced
caspase-dependent apoptosis
[367]
HL-60, K562 15d-PGJ2, troglitazone Induced apoptosis through Bax/Bcl-2
regulation
[368]
Mono Mac 6, U937 15d-PGJ2, troglitazone Induced apoptosis; downregulated
cyclooxygenase-2
[369]
HL-60 15d-PGJ2 PPARγ-independent TRAIL-induced apoptosis [370]
Jurkat, PC3 15d-PGJ2 PPARγ-independent TRAIL-induced apoptosis [371]
EoL-1, U937, KPB-M15 troglitazone Inhibited cell proliferation by G0/G1 arrest [372]
HL-60, K562 15d-PGJ2, troglitazone
Inhibited cell growth, adhesion, and invasion
through Matrigel; inhibited MMP-2 and
MMP-9 expression
[230]
AML DIM #34
Inhibited cell growth; induced apoptosis
through PPARγ-dependent and independent
mechanism
[365]
HL-60, U937, AML, CLL rosiglitazone, 15d-PGJ2,
CDDO
Inhibited cell growth, induced diﬀerentiation,
induced apoptosis when combined with
RXR-selective ligands
[373]
HL-60 Thiazolidinedione Inhibited cell proliferation by G0/G1 arrest;
induced apoptosis; induced diﬀerentiation
[374]
U937 troglitazone Inhibited cell proliferation by G1 arrest [375]
NB4 15d-PGJ2, pioglitazone
Inhibited cell proliferation; induced
diﬀerentiation and lipogenesis when combined
with speciﬁc RXR ligands
[376]
HL-60, AML CDDO-Me Induced cell diﬀerentiation; induced apoptosis [214, 363, 364]
HL-60 CDDO Induced apoptosis; induced diﬀerentiation and
increased phagocytosis at sub-apoptotic doses
[377]
APL, NB4, MR2 CDDO Enhanced all-trans-retinoic acid-induced
diﬀerentiation and apoptosis
[378]
AML CDDO Induced apoptosis in a caspase-dependent and
independent manner
[379]
U937 CDDO-Im
Inhibited cell proliferation; induced
diﬀerentiation through PPARγ-independent
mechanism
[50]
U937 CDDO, CDDO-Me,
CDDO-Im
Induced apoptosis by increasing reactive
oxygen species and decreasing intracellular
glutathione
[380]
THP-1 rosiglitazone Inhibited 9-cis retinoic acid-induced cell
growth
[381]
THP-1 troglitazone,
rosiglitazone Inhibited MCP-1-induced migration [382]
K562, KU812, KCL22,
BV173, SD1, SupB-15 TZD18
Inhibited cell growth through a
PPARγ-independent mechanism; inhibited
proliferation; induced apoptosis
[359, 383]
K562 troglitazone,
pioglitazone
Inhibited cell proliferation and erythroid
phenotype; downregulated GATA-1
[384]
B-ALL 15d-PGJ2, pioglitazone
Inhibited cell growth by G1 arrest; induced
apoptosis partially dependent on caspase
signaling
[385]
UTree-O2, Bay91, 380 troglitazone Inhibited cell growth by G1 arrest; induced
apoptosis; downregulates c-myc expression
[386]4 PPAR Research
Table 2: Continued.
Hematological
malignancy/cell line PPARγ agonist Comments Ref
U266, RPMI 8226, BL-41,
HS-Sultan 15d-PGJ2
Induced apoptosis; downregulation of
NF-κB-dependent antiapoptotic proteins
[387]
Jurkat, J-Jahn, T-ALL 15d-PGJ2,P G D 2 Induced apoptosis through PPARγ-dependent
mechanism
[388]
Karpas 299 15d-PGJ2, GW7845,
rosiglitazone
I n d u c e dc e l ld e a t ha th i g hl i g a n dc o n c e n t r a t i o n
b u tp r o m o t e dc e l ls u r v i v a la tl o wd o s e s
[389]
CTCL and Sezary
syndrome cell lines: MJ,
Hut78, and HH
CDDO
Induced apoptosis through a
PPARγ-independent mechanism by decreasing
antiapoptotic protein Bcl-xL and activating
caspase 3
[390]
GRANTA-519, Hbl-2,
JeKo-1
15d-PGJ2, rosi-glitazone,
pioglitazone
Induced apoptosis and downregulation of
cyclin D1
[391]
CLL B cells CDDO Induced apoptosis in part by activation of
caspase-8
[392]
CLL B cells, Jurkat CDDO Induced apoptosis through the intrinsic
pathway
[393]
DLBCL CDDO Inhibited proliferation; induced apoptosis
through a PPARγ-independent mechanism
[47]
Primary B lymphocytes,
Ramos, OCI-Ly19 DLBCL
CDDO, CDDO-Im,
Di-CDDO
Induced apoptosis through a mitochondrial
dependent pathway
[394]
ANBL6, RPMI 8226 15d-PGJ2, ciglitazone Induced apoptosis via caspase activation and
mitochondrial depolarization
[208]
LP-1, U-266, RPMI
8226-S, OPM-2, IM-9
rosiglitazone,
pioglitazone, 15d-PGJ2
Inhibited tumor cell growth [395]
Waldenstrom’s
macroglobulinemia rosiglitazone, ciglitazone Inhibited cell growth; induced apoptosis [396]
multiple myeloma (MM)
drug sensitive MM.1S or
drug resistant MM.1R
cells, KAS6/1, ANBL-6
15d-PGJ2, troglitazone
Inhibited cell adhesion to BMSCs and
adhesion-triggered IL-6 production; overcame
resistance to dexamethasone (MM.1R cells)
[212]
MM cells, U266, RPMI
8226, bone marrow
mononuclear cells
CDDO, CDDO-Im Induced apoptosis by disruption of
mitochondrial membrane potential
[397]
Dexamethasone-resistant
MM.R1, RPMI
8226/LR-5, RMPI
8226/Dox-40, U266
CDDO-Im Induced apoptosis; decreased MM
adhesion-triggered IL-6 production
[398]
RPMI 8226, JJN3 CDDO-Im Inhibited Stat3 and Stat5 phosphorylation;
induced Stat inhibitors SOCS-1 and SHP-1
[399]
Normal human B cells
and B lymphoma cells
(Daudi, Ramos, Raji)
rosiglitazone,
pioglitazone, 15d-PGJ2
Inhibited cell proliferation; induced apoptosis [209]
MM cell lines (RPMI 8226
and U266); BMSCs, HS-5
PPARγ over-expression;
ciglitazone
PPARγ overexpression inhibited proliferation
and induced apoptosis in MM cells; inhibited
IL-6 production in BMSCs
[207]
Bc e l ll y m p h o m a( R a j i ,
Ramos cell lines) PPARγ siRNA
Silencing of PPARγ induced cell proliferation
and cell diﬀerentiation; PPARγ knockdown
enhanced NF-κB activity in Ramos cells
[206]PPAR Research 5
2. Tumor-Stromal Microenvironment Crosstalk
andTumor-AssociatedAngiogenesis
2.1. Cancer Stem Cell Theory and Tumor Dormancy. Ak e y
issue of debate in cancer biology is whether tumor growth
is caused by a substantial proportion of the tumor cells or
exclusively by an infrequent subpopulation of cells termed
cancer stem cells (CSCs) [52]. Regardless of the cancer
type, most patients who have experienced many years of
disease-freesurvivalaftersuccessfultreatmentoftheprimary
tumor ultimately die from metastatic disease. Patients who
relapse must harbor cancer cells for years or even decades
until the cancer cells overcome the regulatory mechanisms
that keep the tumor in check. Dormant cancer cells are
deﬁned by a prolonged absence of or a balance in either
proliferation or apoptosis, resulting in essentially a perpetual
state of quiescence that protects them from conventional
cytotoxic drugs, which only target actively proliferating
cells. It is unknown whether dormant cancer cells represent
a specialized subpopulation of cells programmed to stay
dormant, an unspecialized population of cells not able to
grow in the new microenvironment, or a combination of
both [53]. CSCs are usually slowly cycling cells and thus
insensitive to cytotoxic drugs as well [54, 55]. Dormant
cancer cells are inferred to be CSCs or tumor initiating cells,
as some prefer to call them [56]. Nonetheless, the relative
frequency of CSCs varies as a function of both the tumor
type and the speciﬁc experimental system used [57]. To date,
published data most strongly support the presence of CSCs
in hematologic malignancies such as leukemia [58], and in
three major solid tumor types, including aggressive brain,
breast, and colon cancers [59, 60]. Moreover, the existence
of treatment resistant tumor cells following disease relapse
has bolstered the theory that CSCs exist [56]. Thus, new
approaches to target CSCs are actively being sought.
Although little evidence is available to suggest whether
PPARγ agonists could be used to speciﬁcally target CSCs
while sparing normal hematopoietic stem cells, a few studies
have been reported. Chearwae and Bright [61] demonstrated
that PPARγ agonists inhibit the proliferation of brain
CSCs by inducing cell cycle arrest and apoptosis, which
was associated with upregulated expression of PPARγ and
inhibition of signal transducer and activator of transcription
(Stat)-3 signaling. Saiki and colleagues [62] showed that
pioglitazone inhibits the growth of human leukemia cell
lines and primary leukemia cells while sparing normal stem
cells. Preclinical testing has identiﬁed additional cancer ther-
apeutics that selectively target leukemic stem cells but not
normal stem cells, including idarubicin with the proteasome
inhibitor, parthenolide (known as feverfew), and TDZD-8
[63]. These agents target the NF-κB pathway, a critical link in
the well-established association between inﬂammation and
carcinogenesis. In that PPARγ agonists inhibit both NF-κB-
and Stat3-mediated transactivation of target genes and both
of these transcription factors play a prominent role in cancer
progression (see Section 2.8 and references therein), it is a
likely extension to consider a role for PPARγ agonists to
target CSCs.
2.2. Tumor-Associated Angiogenesis. Regardless of the type of
cancer, once a primary tumor becomes established, it needs
to develop its own blood supply for nutrient delivery and
removal of toxic waste. The process of angiogenesis, that is
theformationofnewbloodvesselsfromexistingvasculature,
involves complex interplay among cancer and stromal cell-
secreted factors, extracellular matrix (ECM) constituents,
and endothelial cells (ECs) (Figure 1). The adult vasculature
is composed of quiescent ECs lining blood vessels and, with
the exception of reproduction; the process of angiogenesis
begins only in response to a broad array of tissue injury.
Several isoforms of VEGF-A/165 are produced by alter-
native mRNA processing of the primary transcript, and these
isoforms diﬀer primarily in their ability to adhere to heparin
or heparan sulfate proteoglycans (HSPGs) found both in the
ECM or on the surface of stromal and tumor cells [72]. The
VEGF gene family encodes VEGF isoforms A-F and placenta
growth factor (PLGF) with at least three cognate receptors,
VEGFR1/Flt-1,VEGFR2/Flk-1/KDR,VEGFR3/Flt-4andtwo
coreceptors, neuropilin (NRP) and HSPGs. VEGF-A/165
(hereafter designated VEGF) signaling through VEGFR2 is
the major isoform responsible for pathological angiogenesis
and induction of vascular permeability in tumors [73, 74],
which leads to enhanced transendothelial migration of can-
cer cells during intravasation and extravasation [75]. VEGF-
C and VEGF-D bind to VEGFR2 as well as VEGFR3 and are
important for lymphangiogenesis and cancer metastasis to
lymph nodes and spread through the lymphatic system [76–
78].
VEGF production and intracrine signaling through
VEGFR2 by ECs is essential for vascular homeostasis but is
dispensable for angiogenesis as shown in EC-speciﬁc VEGF
knockout mice [79]. Intracrine VEGF signaling requires
expression of both VEGF and VEGFRs by the same cell and
resistance to VEGF inhibitors that fail to penetrate the intra-
cellular compartment. Hematopoietic stem cell survival also
involves a VEGF-dependent internal autocrine loop mecha-
nism [80]. Although it was originally thought that VEGFR
expression was restricted to ECs, it is now apparent that
other cell types express functional VEGFRs. Furthermore,
VEGF is an autocrine growth factor for VEGFR-positive
human tumors, including Kaposi sarcoma, melanoma,
breast, ovarian, pancreatic, thyroid and prostate carcinomas,
and leukemia [81–87]. Thus, in VEGFR-expressing tumors,
VEGF inhibition may directly inhibit tumor cell growth
as well as tumor-associated angiogenesis [83]. A host of
proangiogenicfactorsplayaroleinpathologicalangiogenesis
[64]; however, since most anticancer therapeutic strategies
target the VEGF signaling pathway [64, 88], this paper
focuses thereon.
2.3. Tumor-Stromal Microenvironment. Paget’s “seed and
soil” hypothesis emphasizes the importance of the interac-
tion between the tumor cell (“seed”) and its environment
(“soil”) for metastasis to occur (reviewed in [89]). The
stroma of the tumor microenvironment consists of several
components including growth factors, chemokines, matrix
glycoproteins and proteoglycans, proteases, and host cells6 PPAR Research
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Figure 1: Molecular mechanisms of tumor-associated angiogenesis. Angiogenesis is essential for the persistence of solid tumor growth and,
only recently, has it been appreciated that angiogenesis plays a role in progression of hematological malignancies as well. Cancer-associated
angiogenesis in solid tumors begins once the tumor mass reaches a critical size such that the hypoxic environment inside the tumor leads
to cancer cell-speciﬁc expression of proangiogenic factors including VEGF to shift the balance from endogenous antiangiogenic factors to
tumor supplied proangiogenic factors—the angiogenic switch. Once proangiogenic factors overwhelm antiangiogenic factors, new blood
vessels form in response to VEGF-induced endothelial permeability by EC sprouting, migration into the tumor mass, and proliferation from
existing blood vessels—molecular mechanisms also induced by VEGF [64–67]. The tumor integrity of the vasculature is compromised in
that it remains leaky with poor cell-to-cell adhesion, is abnormally branched and not well supported by pericytes (mural cells), the vascular
smooth muscle cells that stabilize normal blood vessels [67, 68]. The chronic immaturity of tumor vessels has led Dvorak to characterize
a tumor as a “wound that never heals” [69]. Notwithstanding, these features make tumor vessels viable targets for antitumor therapies.
Benjamin et al. [70] demonstrated that removal of growth factors leads not only to the cessation of new vessel growth, but also to regression
of the immature tumor vasculature [71].
that inﬂuence the behavior of cancer cells (reviewed in [90–
102]). Host ECs, pericytes, macrophages, dendritic cells,
lymphocytes, adipocytes, and ﬁbroblasts/myoﬁbroblasts
present in the tumor microenvironment participate in the
metastatic process (Figure 2). Initiation of new blood vessel
formation requires activation of matrix metalloproteinases
(MMPs) leading to degradation of the basement membrane,
sprouting of ECs, and regulation of pericyte attachment
for vessel stabilization. Activated ﬁbroblasts, myoﬁbroblasts,
play an important role in synchronizing these events [94].
Furthermore, the topography of the ECM mediates vascular
developmentandregulatesthespeedofcellmigrationduring
angiogenesis [103].
Chronic inﬂammation is associated with cancer ini-
tiation and progression [104–106]. Vascular ECs play a
pivotal role in regulating leukocyte recruitment during
inﬂammation [90]. Thus, in most cases, cancers exploit
inﬂammation and recruited inﬂammatory cells for their own
beneﬁt [91]. Although activated inﬂammatory cells in the
tumor microenvironment play important roles in cancer
initiation, progression, angiogenesis, and metastasis [92],
they are not the most numerous. Cancer-associated ﬁbrob-
lasts, which resemble myoﬁbroblasts of healing wounds, are
the most abundant cells of the tumor stroma [93], and
contributesigniﬁcantlytochronicinﬂammation,production
of proangiogenic factors, and metastasis [94].
2.4. Inhibitors of Angiogenesis. As discussed above, angiogen-
esis is the hallmark pathology in tumor growth, progression,
and metastasis. Inhibiting tumor angiogenesis adds to the
a r s e n a lo ft r e a t m e n to p t i o n sf o ran u m b e ro fs o l i dt u m o r
types [111, 112], and recently has been proposed for hema-
tological malignancies as well [107, 113–119]. Endogenous
inhibitors of angiogenesis are critical for tight regulation of
pathologicalangiogenesis;however,inresponsetomalignant
transformation the putative “angiogenic switch” bypasses
this tight regulation to promote tumor progression [120].
Whereas radiation and chemotherapy target killing of the
tumor cells, antiangiogenic therapy is primarily directed
against tumor blood vessels. Endostatin [121, 122], angio-
statin [122], and TSP-1 [123] are among a host of well-
known endogenous inhibitors of angiogenesis [98, 124].
TSP-1 is a large molecular weight glycoprotein that inhibits
the proliferation and migration of ECs by interacting with
CD36 expressed on the cell surface; CD36 is a PPARγ target
gene. Small molecules based on a CD36-binding peptide
sequence from TSP-1 are being tested for cancer treatment.
Oneanalog,ABT510,exhibitspotentproapoptoticactivityin
vitro, while clinically it is very well tolerated with therapeutic
beneﬁts against several malignancies reported in phase II
clinical trials [125–129].
Targeting VEGF-induced angiogenesis is in current use
as monotherapy or combination therapy to treat a wide var-
iety of cancers [130–132]. Bevacizumab (Avastin) and rani-
bizumab (Lucentis) are FDA-approved humanized mono-
clonal antibodies that recognize and block VEGF signaling
in cancer and age-related macular degeneration (AMD)
[130–134]. Additional, but not all-inclusive VEGF inhibitorsPPAR Research 7
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Figure 2: Tumor-associated angiogenesis is sustained through stromal microenvironment crosstalk. Most tumors are associated with the
activation of tumor-promoting innate immune responses involving neutrophils, macrophages, and NK cells. Speciﬁc (adaptive) antitumor
immuneresponsesinvolvingT-orB-lymphocytesarelesseﬃcientinsuppressingtumorgrowth.Increasedformationofbloodandlymphatic
vessels in bone marrow and lymph nodes provide oxygen and nutrients to malignant cells. Stromal cells, including ECs, inﬂammatory cells,
and ﬁbroblasts/myoﬁbroblasts, produce cytokines and growth factors that act in a paracrine fashion to promote malignant cell proliferation
or survival. In turn, malignant cells produce angiogenic factors and express their cognate receptors establishing functional autocrine loops
to perpetuate their survival including signaling through the VEGF pathway [85–87, 107]. The secreted factors produced by and in response
to those secreted by stromal and tumor cells include, but are not limited to VEGF, FGF-2, PDGF, IGF-1, HSF, TGF-α,T G F - β,T N F - α,I L -
8, MCP-1/CCL2, MIF, IL-6, and IL-1 [95]. The potent vasoconstrictor peptide endothelin-1 has been implicated in the pathophysiology
of atherosclerosis and its complications [108], as well as tumor angiogenesis and lymphangiogenesis [109, 110]. Proteases important for
invasion thorough the basement membrane and remodeling of the ECM, such as plasminogen [96] and MMPs, including MMP-2 and
MMP-9[97],andtheirinhibitors,PAI-1/2andTIMPs,respectively,areproducedbystromalandtumorcells.Downregulationofendogenous
inhibitors of angiogenesis such as thrombospondin (TSP)-1 occurs in the stromal compartment as well to favor angiogenesis, cancer cell
growth, and metastasis [98]. In recent years, it has been recognized that a better understanding of the tumor-stromal microenvironment
crosstalk may lead to elucidation of new therapeutic strategies for cancer therapy [99–102].
(direct or indirect) are the RNA aptamer, pegaptanib; VEGF
receptor decoy, VEGF-Trap (Aﬂibercept); small interfer-
ing RNA-based therapies, bevasiranib, and AGN211745;
rapamycin, sirolimus; tyrosine kinase inhibitors includ-
ing vatalanib, pazopanib, imatinib (Gleevec), TG100801,
TG101095, AG013958, and AL39324; soluble VEGFRs; pro-
teasome inhibitors, bortezomib (Velcade); thalidomide and
derivatives.
At present, established therapies have been very success-
ful in reducing the vision loss associated with AMD [135,
136]; however, a number of reports on the clinical outcomes
of antiangiogenic therapy with VEGF inhibitors have shown
equivocal results [88, 137–141]. Unfortunately, no signiﬁ-
cant survival beneﬁt has been demonstrated in anti-VEGF
monotherapy trials. When anti-VEGF inhibitors are used
in combination with standard chemotherapeutic approaches
for solid tumors, such treatment does not prolong survival
of cancer patients for more than a few months [137–141],
except as shown in phase II and phase III clinical trials for
metastatic colon cancer and metastatic breast cancer where
median survival over chemotherapy alone was extended
∼ 15–26 months (reviewed in [142]). Although diﬀerent
classes of VEGF-targeted therapies inhibit primary tumor
growth, recent studies surprisingly report that treatment
with VEGF inhibitors leads to more invasive and metastatic
tumors [139, 143]. Most patients who initially respond
to VEGF-targeted therapy will develop resistance, and the
molecular and cellular mechanisms promoting resistance are
poorly understood [137, 138]. Thus, resistance or refractori-
ness of tumor ECs to treatment with VEGF inhibitors limits
the utility of long-term treatment [143]. These ﬁndings
indicate that new studies and molecular approaches are
needed to overcome the lack of sensitivity or resistance of
tumor ECs to antiangiogenic therapies.
2.5. Targeting Transcription Factor Signaling Pathways Acti-
vated in Angiogenesis. Although VEGF is upregulated in
response to many inducers activated in cancer, only two
major transcription factors have been identiﬁed for its
promoter, hypoxia inducible factor (HIF)-1 and Stat3 [144].
Both HIF-1 production and Stat3 activity are upregulated
in many types of cancer. VEGF is strongly induced by the8 PPAR Research
hypoxictumormicroenvironmentbeforethetumorbecomes
vascularized, and thus, is important in hypoxic regulation of
angiogenesis [145, 146]. HIF-1 is composed of the constitu-
tively expressed HIF-1β subunit (aka the aryl hydrocarbon
nuclear translocator/ARNT [146]) and an O2-a n dg r o w t h
factor-regulated HIF-1α subunit. HIF-1α is also constitu-
tively expressed but rapidly degraded under normoxia due
to hydroxylation at two proline residues within the central
degradation domain. Hydroxylation increases the aﬃnity of
HIF-1α for the tumor suppressor protein von Hippel-Lindau
(pVHL) E3 ligase complex, which mediates ubiquitination
and proteasomal degradation of HIF-1α thereby preventing
formation of an active HIF-1 heterodimer [147]. Because
the HIF hydroxylases have an absolute requirement for oxy-
gen, hydroxylation is suppressed under hypoxic conditions
allowing the HIF-1α subunit to accumulate, translocate to
the nucleus, and heterodimerize with HIF-1β to activate
transcription of target genes [148].
Activation of the Jak/Stat3 pathway by IL-6 through
its high aﬃnity receptor, IL-6Rα, and its binding partner,
gp130, is a well-known inﬂammatory response evoked by
the acute phase response of innate immunity [149, 150].
Stat3 is a latent transcription factor whose maximal acti-
vation requires both tyrosine (Y-705) and serine (S-727)
phosphorylation. Inhibition of Stat3 activation blocks HIF-
1 and VEGF expression in vitro and inhibits tumor growth
and angiogenesis in vivo [151]. Activation of Stat3 signaling
by various mitogens is prevalent in diﬀerent types of cancers.
Furthermore, when Stat3 is inhibited, tumor cells will no
longer express proangiogenic mediators in response to IL-6R
signaling. Because Stat3 is constitutively active in many types
of cancers, it is considered oncogenic [152, 153]. Therefore,
Stat3 is an apt upstream target for inhibiting tumor VEGF
expression and angiogenesis [151].
NF-κB transcription factor links inﬂammation and
tumorigenesis, and its activation allows both premalignant
and malignant cells to escape apoptosis [154]. NF-κBs i g -
naling occurs in essentially all aspects of cancer progression
from uncontrolled growth, evasion of apoptosis, tumor cell
invasion through stromal compartments and into the blood
stream, and sustained angiogenesis [104, 154]. Constitutive
NF-κB activation is found in lymphoid and myeloid malig-
nancies, including preneoplastic conditions, emphasizing its
role in malignant transformation [155, 156]. More than
200 genes involved in cell survival, apoptosis, cell growth,
immune responses and inﬂammation are transactivated
by NF-κB[ 157]. NF-κB is sequestered in the cytoplasm
by inhibitor proteins such as IκBα [104, 154–156]. Upon
activation, proteasomal degradation of IκBα releases NF-
κB, which then translocates to the nucleus to bind to the
κB response element in promoter regions of target genes.
Thus, small inhibitory molecules that target these various
steps are continually being sought for cancer treatment.
PPARγ agonists have anti-inﬂammatory properties that
are conferred, in part, through their ability to inactivate
transcription factors that regulate inﬂammation including
Stat3, NF-κB, and AP-1 [158–160]. The potential for PPARγ
agonists as inhibitors of Stat3 and NF-κB survival signaling
in hematological malignancies is discussed in Section 2.8.
2.6. Angiogenesis and Targeted Antiangiogenic Therapy in
Hematological Malignancies. Since hematological malignan-
cies originate in bone marrow and lymphatic organs and do
not form solid tumor masses, it was generally believed that
angiogenesis would not be as critical for cancer progression
as in solid tumors. In the recent years, however, the
importanceofangiogenesisandlymphangiogenesisinhema-
tological malignancies has been recognized and discussed in
detail in a number of excellent reviews and references therein
[113,114,116–119].BecausePPARγ agonistsarebeingtested
as inhibitors of angiogenesis, it is important to understand
the role of angiogenesis and associated signal transduction
pathways in the progression of hematological malignancies.
Increased bone marrow microvessel density (MVD), an in
vivo measure of tumor-associated angiogenesis, is found in
hematological malignancies [161], conﬁrming the impor-
tance of angiogenesis for malignant progression.
In general, increased MVD correlates with increased
disease burden and poor prognosis or treatment outcome
[118]. A number of antiangiogenic agents have been used to
treat hematological malignancies as discussed in the review
articlescitedabove.Forexample,thalidomide,wellknownas
a potent teratogen causing stunted limb growth, has gained
favor as an inhibitor of angiogenesis in multiple myeloma
(MM) [162–167]. Thalidomide and similar immunomod-
ulatory drugs and proteasome inhibitors (e.g., bortezomib)
exert their eﬀects directly by induction of apoptosis of MM
cells or indirectly by inhibiting production of cytokines and
proangiogenic factors, including VEGF, by bone marrow
stromal cells (BMSCs) [162, 168]. The angiogenic activity
of MM ECs correlates with downregulated expression of
the endogenous antiangiogenic factor, endostatin [169].
Increased MVD in bone marrow correlates with shorter
overall disease-free survival in AML, and elevated VEGF
mediates both autocrine and paracrine signaling in support
of leukemia cell survival and induction of angiogenesis [86,
87, 113, 161].
Angiogenesis in chronic lymphocytic leukemia (CLL)
occurs in both marrow and lymph nodes [170]. Increased
vascularity leads to elevated production of hematopoietic
growth factors by new vessel ECs, which stimulates expres-
sion of VEGF and VEGFRs by CLL cells for autocrine
signaling to promote survival [113, 170]. Elevated lev-
els of VEGF are found in the serum of patients with
chronic myeloid leukemia (CML), which correlates with
w o r s es u r v i v a l[ 171]. Non-Hodgkin lymphoma (NHL) cells
secrete VEGF and express VEGFRs, which also contribute
to autocrine and paracrine signaling [172]. A phase II
clinical trial of bevacizumab (Avastin) therapy in patients
with relapsed, aggressive NHL showed a median increase
in disease-free survival by 5.2 months [115], suggesting
that anti-VEGF therapy is a limited but viable target for
treatment. Antiangiogenic therapy would likely be more
eﬃcacious if combined with active chemotherapy regimens
[115, 173]. Increased MVD in lymph nodes and elevated
VEGF are statistically correlated with a greater tumor
burden in Hodgkin lymphoma in newly diagnosed patients
[174, 175]. Survival after treatment of diﬀuse large-B-cell
lymphoma is adversely aﬀected in patients whose tumorPPAR Research 9
stroma show elevated MVD, indicating that diﬀerences in
the tumor microenvironment play a critical role in treatment
outcomes [176]. However, the role of angiogenesis varies in
lymphoma subtypes due to heterogeneity in expression of
proangiogenic factors [113, 177].
In addition to agents targeting VEGF-VEGFR signaling
directly, a number of agents have been developed to tar-
get the tumor microenvironment (reviewed in [99–102]),
including ECM modulators, tyrosine kinase inhibitors, and
immunomodulators, many of which indirectly target cancer
angiogenesis. Nonetheless, autocrine VEGF signaling to
promote malignant cell survival appears to be a common
theme in hematological malignancies [85–87, 107, 113,
170, 172, 178], suggesting that anti-VEGF/VEGFR targeted
therapy would promote direct killing of tumor cells, as
well as inhibit angiogenesis associated with several types of
hematological malignancies. It should be noted that antian-
giogenic therapy in combination with conventional therapy
for metastatic colon cancer and metastatic breast cancer
signiﬁcantly increased survival [142]; these cancers represent
two of the three solid tumors (the third being brain cancer)
for which published data most strongly support the presence
of CSCs [59, 60]. In that CSCs have been documented
in hematologic malignancies such as leukemia [58], it is
interesting to speculate that patients with hematological
malignancies other than leukemias may beneﬁt from adding
antiangiogenic therapy to standard treatments if CSCs could
be identiﬁed in the malignant population of cells.
2.7. Eﬀects of PPARγ and PPARγ Ligands on EC Functions
and Angiogenesis. The endothelium releases a balance of
bioactive factors that regulate vasoconstriction and relax-
ation to facilitate vascular homeostasis [179]. During home-
ostasis, the endothelium also inhibits platelet and leukocyte
adhesion to the vascular surface and maintains the balance
betweenprothromboticandproﬁbrinolyticactivities.Several
common conditions with a predisposition to atherosclerosis,
including hypercholesterolemia, hypertension, diabetes, and
stroke, are associated with endothelial dysfunction, lead-
ing to a proinﬂammatory and prothrombotic endothelium
[180]. For more than a decade investigators have studied the
eﬀects of PPARγ ligands on EC functions with a particular
interest in determining whether they could be used to
inhibit cancer cell growth (reviewed in [25, 31, 181, 182])
and cancer-associated angiogenesis (reviewed in [23, 25, 31,
181–184]). The functions that PPARγ ligands target during
angiogenesis include induction of apoptosis, inhibition of
EC proliferation, downregulation of proangiogenic factors,
and as inhibitors of the inﬂammatory events that trigger and
perpetuate pathological angiogenesis (Table 3). In addition
to targeting tumor angiogenesis, PPARγ ligands have direct
eﬀects on cancer cells due to their ability to promote
apoptosis, inhibit cell proliferation or induce diﬀerentiation
[3, 71, 185–188]. However, to date, disappointing results
have been obtained in phase II clinical trials using the PPARγ
ligand troglitazone to inhibit progression of treatment-
refractory metastatic breast cancer [189], chemotherapy-
resistantmetastaticcolorectalcancer[190],andprostatecan-
cer [191]. In recent years, the focus has shifted from treating
the tumor to targeting the signaling pathways that drive
aberrantcellproliferationandsurvivalandtumor-associated
angiogenesis. Such targets have the potential for greater
speciﬁcity together with reduced systemic toxicity [104].
2.8. TherapeuticPotentialofPPARγandPPARγ Ligands to Ta-
rget Angiogenic Signaling Pathways in Treatment of Hematolo-
gical Malignancies. It has been suggested that PPARγ fun-
ctions as a tumor suppressor gene [204]; therefore, it is
important to understand the complexity of signal tra-
nsductionpathwaysandmolecularplayersaﬀectedbyPPARγ
that promote tumor growth, cancer-associated angiogenesis,
andmetastasis.MM,aprogressivehematologicalmalignancy
of plasma cells, remains largely incurable with survival ave-
raging 3–5 years despite conventional and high-dose the-
rapies; therefore, novel treatment approaches are desperately
needed. MM is characterized by excessive numbers of
abnormal plasma cells in the bone marrow and overpro-
duction of intact monoclonal immunoglobulin (IgG, IgA,
IgD, or IgE) or Bence Jones protein (free monoclonal κ
and λ light chains). Common clinical manifestations of
MM are hypercalcemia, anemia, renal damage, increased
susceptibility to bacterial or viral infection, and impaired
production of normal immunoglobulins (http://www.them-
mrf.org/living-with-multiple-myeloma/newly-diagnosed-p-
atients/what-is-multiple-myeloma/deﬁnition.html).Lyticle-
sions are often found in the bone including the pelvis, spine,
ribs, and skull. Furthermore, neovascularization in bone
marrow parallels disease progression of MM [205].
Our laboratory has shown that normal and malignant B
cells, including MM, express PPARγ [206–210], and that cer-
tain PPARγ ligands can induce apoptosis in MM cells [207,
208]. Because PPARγ ligands also have PPARγ-independent
eﬀects, we examined the functional consequences of PPARγ
overexpression in human MM [207]. PPARγ overexpression
in myeloma cells decreased cell proliferation, induced spon-
taneous apoptosis even in the absence of exogenous ligand,
and enhanced their sensitivity to PPARγ ligand-induced
apoptosis.Apoptosiswasassociatedwiththedownregulation
of anti-apoptotic proteins XIAP and Mcl-1 as well as induc-
tion of caspase-3 activity [207]. IL-6 mediates growth and
survival of human myeloma cells through the MEK/MAPK
and Jak/Stat signaling pathways, and IL-6 confers protection
against dexamethasone-induced apoptosis via activation of
the protein tyrosine phosphatase, SHP2 [211]. Binding of
MMcellstoBMSCstriggersexpressionofadhesivemolecules
and secretion of IL-6, promoting MM cell growth, sur-
vival, drug resistance, and migration. Furthermore, PPARγ
overexpression-induced cell death of myeloma cells is not
abrogated by coculture with BMSCs [207]. Overexpression
of PPARγ in myeloma cells and BMSCs inhibited both
basal and myeloma cell adhesion-induced IL-6 production
by BMSCs. These results indicate that PPARγ negatively
controls MM growth and viability, in part, through inhi-
bition of IL-6 production by BMSCs [207]. Wang et al.
[211] showed that myeloma cells express PPARγ and that
thePPARγ agonists,15d-PGJ2 andtroglitazone,abolishIL-6-
inducible myeloma cell proliferation and promote apoptosis10 PPAR Research
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f
o
r
i
n
v
i
t
r
o
a
c
t
i
v
i
t
i
e
s
•
A
n
t
i
-
p
r
o
l
i
f
e
r
a
t
i
o
n
a
c
t
i
v
i
t
y
i
n
E
C
•
A
n
t
i
-
i
n
v
a
s
i
o
n
a
c
t
i
v
i
t
y
o
f
E
C
•
C
o
o
p
e
r
a
t
i
v
e
i
n
h
i
b
i
t
i
o
n
o
f
E
C
a
n
g
i
o
g
e
n
i
c
f
u
n
c
t
i
o
n
s
•
S
y
n
e
r
g
i
s
t
i
c
i
n
h
i
b
i
t
i
o
n
o
f
t
u
m
o
r
a
n
g
i
o
g
e
n
e
s
i
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T
a
b
l
e
3
:
C
o
n
t
i
n
u
e
d
.
R
e
f
.
G
o
a
l
o
f
S
t
u
d
y
R
e
s
u
l
t
s
P
r
o
-
o
r
a
n
t
i
a
n
g
i
o
g
e
n
i
c
D
i
r
e
c
t
o
r
I
n
d
i
r
e
c
t
E
ﬀ
e
c
t
s
[
1
9
7
]
T
o
d
e
t
e
r
m
i
n
e
w
h
e
t
h
e
r
P
P
A
R
γ
a
g
o
n
i
s
t
s
m
o
d
u
l
a
t
e
b
o
n
e
m
a
r
r
o
w
-
d
e
r
i
v
e
d
b
i
p
o
t
e
n
t
i
a
l
A
P
C
s
t
o
p
r
o
m
o
t
e
e
n
d
o
t
h
e
l
i
a
l
l
i
n
e
a
g
e
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
a
n
d
r
e
-
e
n
d
o
t
h
e
l
i
a
l
i
z
a
t
i
o
n
a
f
t
e
r
v
a
s
c
u
l
a
r
i
n
t
e
r
v
e
n
t
i
o
n
.
R
o
s
i
g
l
i
t
a
z
o
n
e
p
r
o
m
o
t
e
d
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
o
f
b
o
n
e
m
a
r
r
o
w
-
d
e
r
i
v
e
d
A
P
C
s
t
o
w
a
r
d
t
h
e
e
n
d
o
t
h
e
l
i
a
l
l
i
n
e
a
g
e
a
n
d
a
t
t
e
n
u
a
t
e
d
r
e
s
t
e
n
o
s
i
s
a
f
t
e
r
a
n
g
i
o
p
l
a
s
t
y
i
n
C
5
7
/
B
L
6
m
i
c
e
;
r
o
s
i
g
l
i
t
a
z
o
n
e
i
n
h
i
b
i
t
e
d
A
P
C
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
t
o
w
a
r
d
s
m
o
o
t
h
m
u
s
c
l
e
c
e
l
l
l
i
n
e
a
g
e
.
•
P
r
o
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
N
o
t
r
e
p
o
r
t
e
d
•
A
n
t
i
-
i
n
ﬂ
a
m
m
a
t
o
r
y
•
P
r
o
m
o
t
e
d
l
i
n
e
a
g
e
-
s
p
e
c
i
ﬁ
c
d
i
ﬀ
e
r
e
n
t
i
a
t
i
o
n
[
1
9
8
]
T
o
d
e
t
e
r
m
i
n
e
t
h
e
e
ﬃ
c
a
c
y
o
f
p
i
o
g
l
i
t
a
z
o
n
e
t
o
i
n
h
i
b
i
t
c
o
r
n
e
a
l
n
e
o
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
.
P
P
A
R
γ
l
i
g
a
n
d
p
i
o
g
l
i
t
a
z
o
n
e
d
e
c
r
e
a
s
e
d
M
V
D
i
n
a
V
E
G
F
-
i
n
d
u
c
e
d
n
e
o
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
i
n
a
r
a
t
c
o
r
n
e
a
m
o
d
e
l
.
•
A
n
t
i
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
i
n
t
h
e
e
y
e
N
o
t
r
e
p
o
r
t
e
d
[
2
4
]
T
o
d
e
t
e
r
m
i
n
e
w
h
e
t
h
e
r
P
P
A
R
γ
l
i
g
a
n
d
s
c
a
n
i
n
h
i
b
i
t
a
n
g
i
o
g
e
n
e
s
i
s
i
n
A
5
4
9
l
u
n
g
c
a
n
c
e
r
c
e
l
l
x
e
n
o
g
r
a
f
t
i
n
v
i
v
o
a
n
d
w
h
i
c
h
s
i
g
n
a
l
i
n
g
p
a
t
h
w
a
y
i
s
i
n
v
o
l
v
e
d
i
n
v
i
t
r
o
.
P
P
A
R
γ
l
i
g
a
n
d
s
t
r
o
g
l
i
t
a
z
o
n
e
a
n
d
p
i
o
g
l
i
t
a
z
o
n
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
i
n
h
i
b
i
t
e
d
A
5
4
9
p
r
i
m
a
r
y
t
u
m
o
r
g
r
o
w
t
h
i
n
S
C
I
D
m
i
c
e
,
l
i
k
e
l
y
d
u
e
t
o
i
n
h
i
b
i
t
i
o
n
o
f
c
a
n
c
e
r
-
a
s
s
o
c
i
a
t
e
d
a
n
g
i
o
g
e
n
e
s
i
s
;
i
n
v
i
t
r
o
s
t
u
d
i
e
s
o
n
A
5
4
9
c
e
l
l
s
s
u
g
g
e
s
t
e
d
P
P
A
R
γ
l
i
g
a
n
d
s
i
n
h
i
b
i
t
c
h
e
m
o
k
i
n
e
e
x
p
r
e
s
s
i
o
n
a
n
d
i
n
h
i
b
i
t
N
F
-
κ
B
a
c
t
i
v
i
t
y
,
t
h
e
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
n
e
c
e
s
s
a
r
y
f
o
r
c
h
e
m
o
k
i
n
e
e
x
p
r
e
s
s
i
o
n
.
•
A
n
t
i
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
D
i
r
e
c
t
a
n
d
i
n
d
i
r
e
c
t
•
I
n
h
i
b
i
t
e
d
N
F
-
κ
B
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
a
c
t
i
v
i
t
y
[
1
9
9
]
T
o
d
e
t
e
r
m
i
n
e
e
ﬀ
e
c
t
s
o
f
P
P
A
R
γ
l
i
g
a
n
d
s
o
n
V
E
G
F
e
x
p
r
e
s
s
i
o
n
b
y
h
u
m
a
n
e
n
d
o
m
e
t
r
i
a
l
c
e
l
l
s
.
P
P
A
R
γ
l
i
g
a
n
d
s
r
o
s
i
g
l
i
t
a
z
o
n
e
a
n
d
1
5
d
-
P
G
J
2
r
e
p
r
e
s
s
e
d
V
E
G
F
g
e
n
e
e
x
p
r
e
s
s
i
o
n
t
h
r
o
u
g
h
a
P
P
R
E
i
n
t
h
e
V
E
G
F
p
r
o
m
o
t
e
r
.
•
A
n
t
i
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
N
o
t
r
e
p
o
r
t
e
d
•
I
d
e
n
t
i
ﬁ
e
d
P
P
R
E
i
n
V
E
G
F
p
r
o
m
o
t
e
r
[
2
0
0
]
B
e
c
a
u
s
e
e
n
d
o
t
h
e
l
i
a
l
p
r
e
c
u
r
s
o
r
c
e
l
l
(
E
P
C
)
f
u
n
c
t
i
o
n
i
s
i
m
p
a
i
r
e
d
i
n
t
y
p
e
2
d
i
a
b
e
t
i
c
p
a
t
i
e
n
t
s
a
n
d
E
C
d
y
s
f
u
n
c
t
i
o
n
c
a
n
b
e
a
m
e
l
i
o
r
a
t
e
d
b
y
t
r
e
a
t
m
e
n
t
w
i
t
h
T
Z
D
s
,
t
h
i
s
s
t
u
d
y
a
s
k
e
d
w
h
e
t
h
e
r
T
Z
D
s
a
ﬀ
e
c
t
t
h
e
n
u
m
b
e
r
a
n
d
f
u
n
c
t
i
o
n
o
f
E
P
C
s
.
R
o
s
i
g
l
i
t
a
z
o
n
e
i
m
p
r
o
v
e
d
n
u
m
b
e
r
a
n
d
m
i
g
r
a
t
o
r
y
a
c
t
i
v
i
t
y
o
f
E
P
C
s
f
r
o
m
t
y
p
e
2
d
i
a
b
e
t
i
c
p
a
t
i
e
n
t
s
;
r
o
s
i
g
l
i
t
a
z
o
n
e
i
n
c
r
e
a
s
e
d
t
h
e
C
D
1
3
3
+
s
u
b
p
o
p
u
l
a
t
i
o
n
o
f
C
D
3
4
+
c
e
l
l
s
(
s
t
e
m
c
e
l
l
s
)
;
r
o
s
i
g
l
i
t
a
z
o
n
e
i
n
c
r
e
a
s
e
d
c
i
r
c
u
l
a
t
i
n
g
l
e
v
e
l
s
o
f
V
E
G
F
;
e
ﬀ
e
c
t
s
m
a
y
b
e
d
u
e
t
o
i
n
c
r
e
a
s
e
d
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
o
f
N
O
b
y
A
k
t
-
d
e
p
e
n
d
e
n
t
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
o
f
e
N
O
S
—
a
p
a
t
h
w
a
y
t
h
a
t
i
s
a
c
t
i
v
a
t
e
d
b
y
V
E
G
F
o
r
t
h
e
i
n
s
u
l
i
n
s
i
g
n
a
l
i
n
g
c
a
s
c
a
d
e
.
•
P
r
o
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
N
o
t
r
e
p
o
r
t
e
d
•
A
k
t
s
u
r
v
i
v
a
l
p
a
t
h
w
a
y
a
c
t
i
v
a
t
e
d
•
E
l
e
v
a
t
e
d
C
D
1
3
3
+
/
C
D
3
4
+
s
t
e
m
c
e
l
l
s
t
o
w
a
r
d
s
E
C
l
i
n
e
a
g
e
(
V
E
-
c
a
d
h
e
r
i
n
+
a
n
d
C
D
3
1
+
)
[
2
0
1
]
T
o
d
e
t
e
r
m
i
n
e
w
h
e
t
h
e
r
T
Z
D
s
i
n
c
r
e
a
s
e
t
h
e
n
u
m
b
e
r
o
f
b
o
n
e
m
a
r
r
o
w
-
d
e
r
i
v
e
d
E
P
C
s
i
n
m
i
c
e
a
n
d
t
h
e
s
i
g
n
a
l
i
n
g
p
a
t
h
w
a
y
s
a
c
t
i
v
a
t
e
d
.
T
r
e
a
t
m
e
n
t
o
f
m
i
c
e
w
i
t
h
p
i
o
g
l
i
t
a
z
o
n
e
u
p
r
e
g
u
l
a
t
e
d
b
o
n
e
m
a
r
r
o
w
a
n
d
c
i
r
c
u
l
a
t
i
n
g
E
P
C
s
;
p
i
o
g
l
i
t
a
z
o
n
e
p
r
e
v
e
n
t
e
d
a
p
o
p
t
o
s
i
s
o
f
h
u
m
a
n
a
n
d
m
o
u
s
e
E
P
C
s
i
n
a
P
I
3
K
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
i
n
v
i
t
r
o
.
•
P
r
o
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
N
o
t
r
e
p
o
r
t
e
d
;
i
n
d
i
r
e
c
t
a
c
t
i
v
a
t
i
o
n
o
f
P
I
3
K
-
A
k
t
n
o
t
a
c
t
i
v
a
t
e
d
b
y
p
i
o
g
l
i
t
a
z
o
n
e
•
P
I
3
K
a
c
t
i
v
a
t
e
d
•
A
n
t
i
-
a
p
o
p
t
o
t
i
c
[
2
7
]
T
o
s
t
u
d
y
t
h
e
e
ﬀ
e
c
t
o
f
P
P
A
R
γ
a
g
o
n
i
s
t
s
o
n
V
E
G
F
-
a
n
d
F
G
F
-
2
-
i
n
d
u
c
e
d
a
n
g
i
o
g
e
n
e
s
i
s
a
n
d
E
C
m
i
g
r
a
t
i
o
n
.
P
i
o
g
l
i
t
a
z
o
n
e
a
n
d
r
o
s
i
g
l
i
t
a
z
o
n
e
i
n
h
i
b
i
t
e
d
t
h
e
p
r
o
a
n
g
i
o
g
e
n
i
c
e
ﬀ
e
c
t
s
o
f
F
G
F
-
2
a
n
d
V
E
G
F
i
n
t
h
e
c
h
i
c
k
c
h
o
r
i
o
a
l
l
a
n
t
o
i
c
m
e
m
b
r
a
n
e
m
o
d
e
l
a
n
g
i
o
g
e
n
e
s
i
s
;
p
i
o
g
l
i
t
a
z
o
n
e
a
n
d
r
o
s
i
g
l
i
t
a
z
o
n
e
i
n
h
i
b
i
t
e
d
V
E
G
F
-
a
n
d
F
G
F
-
2
-
i
n
d
u
c
e
d
E
C
m
i
g
r
a
t
i
o
n
.
•
A
n
t
i
a
n
g
i
o
g
e
n
i
c
i
n
v
i
v
o
n
o
t
r
e
p
o
r
t
e
d
•
I
n
h
i
b
i
t
e
d
E
C
m
i
g
r
a
t
i
o
n
[
2
8
]
T
o
d
e
t
e
r
m
i
n
e
w
h
e
t
h
e
r
a
c
t
i
v
a
t
i
o
n
o
f
P
P
A
R
α
a
n
d
P
P
A
R
γ
s
t
i
m
u
l
a
t
e
s
a
n
g
i
o
g
e
n
e
s
i
s
.
P
P
A
R
α
a
g
o
n
i
s
t
W
Y
1
4
6
4
3
a
n
d
P
P
A
R
γ
a
g
o
n
i
s
t
G
W
1
9
2
9
i
n
d
u
c
e
d
E
C
t
u
b
e
f
o
r
m
a
t
i
o
n
i
n
E
C
/
i
n
t
e
r
s
t
i
t
i
a
l
c
e
l
l
c
o
c
u
l
t
u
r
e
s
b
y
i
n
c
r
e
a
s
i
n
g
V
E
G
F
p
r
o
d
u
c
t
i
o
n
;
W
Y
1
4
6
4
3
a
n
d
G
W
1
9
2
9
i
n
d
u
c
e
d
a
n
g
i
o
g
e
n
e
s
i
s
i
n
m
u
r
i
n
e
c
o
r
n
e
a
l
a
n
g
i
o
g
e
n
e
s
i
s
m
o
d
e
l
a
n
d
A
k
t
a
c
t
i
v
a
t
e
d
i
n
v
i
t
r
o
.
•
P
r
o
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
D
i
r
e
c
t
f
o
r
b
o
t
h
P
P
A
R
α
a
n
d
P
P
A
R
γ
•
I
n
d
u
c
e
d
V
E
G
F
p
r
o
d
u
c
t
i
o
n
•
P
r
o
s
u
r
v
i
v
a
l12 PPAR Research
T
a
b
l
e
3
:
C
o
n
t
i
n
u
e
d
.
R
e
f
.
G
o
a
l
o
f
S
t
u
d
y
R
e
s
u
l
t
s
P
r
o
-
o
r
a
n
t
i
a
n
g
i
o
g
e
n
i
c
D
i
r
e
c
t
o
r
I
n
d
i
r
e
c
t
E
ﬀ
e
c
t
s
[
3
0
]
T
o
i
n
v
e
s
t
i
g
a
t
e
t
h
e
i
m
p
a
c
t
o
f
d
i
a
b
e
t
e
s
o
n
i
s
c
h
e
m
i
a
-
i
n
d
u
c
e
d
c
o
l
l
a
t
e
r
a
l
v
e
s
s
e
l
g
r
o
w
t
h
,
a
n
d
t
e
s
t
e
d
t
h
e
h
y
p
o
t
h
e
s
i
s
t
h
a
t
P
P
A
R
γ
a
g
o
n
i
s
t
s
a
u
g
m
e
n
t
c
o
l
l
a
t
e
r
a
l
ﬂ
o
w
t
o
i
s
c
h
e
m
i
c
t
i
s
s
u
e
.
P
i
o
g
l
i
t
a
z
o
n
e
a
m
e
l
i
o
r
a
t
e
d
e
n
d
o
t
h
e
l
i
a
l
d
y
s
f
u
n
c
t
i
o
n
a
n
d
e
n
h
a
n
c
e
d
b
l
o
o
d
ﬂ
o
w
r
e
c
o
v
e
r
y
a
f
t
e
r
t
i
s
s
u
e
i
s
c
h
e
m
i
a
i
n
d
i
a
b
e
t
i
c
m
i
c
e
;
p
i
o
g
l
i
t
a
z
o
n
e
r
e
s
t
o
r
e
d
V
E
G
F
l
e
v
e
l
s
t
h
a
t
w
e
r
e
r
e
d
u
c
e
d
b
y
i
s
c
h
e
m
i
c
i
n
j
u
r
y
;
A
c
t
i
v
a
t
i
o
n
o
f
e
N
O
S
e
s
s
e
n
t
i
a
l
f
o
r
p
i
o
g
l
i
t
a
z
o
n
e
t
o
p
r
o
m
o
t
e
a
n
g
i
o
g
e
n
e
s
i
s
i
n
i
s
c
h
e
m
i
c
t
i
s
s
u
e
.
•
P
r
o
a
n
g
i
o
g
e
n
i
c
a
c
t
i
v
i
t
y
N
o
t
r
e
p
o
r
t
e
d
•
I
n
d
u
c
e
d
V
E
G
F
p
r
o
d
u
c
t
i
o
n
[
2
0
2
]
T
o
d
e
t
e
r
m
i
n
e
e
ﬀ
e
c
t
s
o
f
r
o
s
i
g
l
i
t
a
z
o
n
e
o
n
g
a
s
t
r
i
c
c
a
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in a PPARγ-dependent manner. These PPARγ agonists also
reduced cell-cell adhesion between BMSCs and MM cells
and overcame resistance to dexamethasone-mediated apop-
tosis in the MM.1R cell line through a PPARγ-dependent
mechanism [212]. Taken together, the results of these studies
demonstrate that PPARγ agonists can be used to inhibit IL-
6-dependent crosstalk between myeloma cells and BMSCs
[207, 211, 212], validating novel therapeutic strategies that
target the tumor-stromal microenvironment.
Dankbar and colleagues [205] demonstrated that biolog-
ically active VEGF is expressed and secreted by myeloma cell
lines and plasma cells isolated from the marrow of patients
with MM. However, the myeloma cells did not express or
onlyweaklyexpressedVEGFR1andVEGFR2,indicatingthat
autocrine VEGF signaling in MM is unlikely. In contrast,
they demonstrated that BMSCs abundantly express VEGFR2
and that such expression could be stimulated in response
to IL-6. In addition, exposure of BMSCs and microvascular
ECs to VEGF induced a time- and dose-dependent increase
in IL-6 secretion. They showed that IL-6-stimulated VEGF
expression in and secretion from myeloma cell lines and in
plasma cells puriﬁed from the marrow of patients with MM
as well. Thus, this study conﬁrms that paracrine interactions
between myeloma and marrow stromal cells triggered by
VEGF and IL-6 represent feasible signal transduction path-
ways to target for treatment of MM [205].
PPARγ ligandsareknowntoinhibitorrepresstheactivity
of a number of transcription factors important in innate
immunity, inﬂammation and cancer, including Stat3 and
NF-κB[ 158, 159]; therefore, targeted inhibition of Stat3 and
NF-κB activity with PPARγ agonists is a relevant avenue
of investigation for new cancer therapeutics [213]. Wang
and colleagues [211] showed that 15d-PGJ2 and troglitazone
signiﬁcantly inhibited Stat3 binding to its cognate response
element and inhibited Stat3 binding to the promoters of
c-MYC and MCL-1 thereby preventing transactivation of
these Stat3 target genes. Whereas 15d-PGJ2 promotes direct
binding of PPARγ to Stat3 forming a complex such that
Stat3 is no longer capable of binding to the type II IL-
6 response element on promoters of Stat3 target genes,
troglitazone induces the redistribution of the corepressor
NCoR/SMRTfromPPARγ toStat3,whichleadstorepression
of Stat3 transactivation of target genes [211]( Figure 3(a)).
In contrast, 15d-PGJ2 and troglitazone did not aﬀect the
expression of IL-6R or activation by phosphorylation of
the downstream signaling molecules Jak/Stat3, MAPK, and
PI3K/Akt in myeloma cells [211].
PPARγ and its ligands eﬀectively blocked IL-6 tran-
scription and secretion from BMSCs that is induced in
response to myeloma cell adhesion [212]. Such inhibi-
tion occurs through competition between PPARγ and NF-
κB for the coactivator PGC-1, which is recruited from
p65/p50complexesbyligand-activatedPPARγ (Figure 3(b)).
Direct complex formation between PPARγ and C/EBPβ
also prevents transactivation of the IL-6 promoter. The
natural PPARγ ligand, 15d-PGJ2,h a saP P A R γ-independent
eﬀect on NF-κB by decreasing phosphorylation of IKK
and IκB to prevent activation of NF-κB[ 212]. Prolonged
treatment with the PPARγ ligand CDDO-Me inactivates
Erk signaling in AML cells eﬀectively inhibiting cell growth
[214]. In vitro studies show that CDDO-Me inactivates
Stat3, Src, and Akt; reduces expression of the c-MYC gene;
promotes accumulation of cells in the G2-M phase of the
cell cycle; and, abrogates invasive growth and induction of
apoptosis of mammary cells [215]. Furthermore, mammary
cell growth and lung metastases were completely eliminated
in mice treated with CDDO-Me starting one day after tumor
implantation;tumorgrowthwassigniﬁcantlyinhibitedwhen
started after 5 days. Thus, CDDO-Me may have therapeutic
potential for hematological malignancies and solid tumors
through inactivation of Stat3 [215].
Bortezomib (Velcade, formerly PS-341) is a proteasome
inhibitor that is used for antiangiogenic therapy in various
cancers including MM [216]. Bortezomib targets myeloma
cells and also inhibits the binding of myeloma cells to
BMSCs. Furthermore, intravenous bortezomib, with or
without dexamethasone, is well tolerated and eﬀective in
treating patients with relapsed or refractory MM [216].
Because bone marrow angiogenesis plays an important role
in the pathogenesis and progression of MM and bortezomib
inhibits angiogenesis, Roccaro and colleagues [217]t e s t e d
the eﬀects of bortezomib on the angiogenic phenotype
of MM patient-derived ECs (MMECs). At clinically rele-
vant concentrations, bortezomib inhibited the proliferation
of MMECs and human umbilical vein endothelial cells
(HUVECs) in a dose-dependent and time-dependent man-
ner. Bortezomib also inhibited angiogenesis as measured
by capillary tube formation on Matrigel in vitro and in
the chick embryo chorioallantoic membrane assay in vivo
[217]. Furthermore, binding of drug sensitive MM cells
(MM.1S) to MMECs triggered their proliferation, which
was prevented by bortezomib. Bortezomib also triggered a
dose-dependent inhibition of VEGF and IL-6 production by
and secretion from MMECs and abrogated IL-6 triggered
signaling cascades via caspase-dependent downregulation of
gp130 in MM [218]; gp130 is the signaling component
of the high aﬃnity IL-6R complex that activates Stat3.
Thesedataprovidemechanisticinsightontheantiangiogenic
eﬀects of bortezomib on MMECs in the bone marrow
microenvironment [217] and support the concept that
adding antiangiogenic agents as adjuvant or combination
therapy with standard therapy would be more eﬃcacious in
treating patients with relapsed or refractory MM [219], and
perhaps other hematological malignancies as well.
Although inhibiting IL-6 signaling through its high
aﬃnity receptor promotes apoptosis of MM cells when
cocultured with BMSCs, some myeloma cells survive sug-
gesting that the marrow microenvironment stimulates IL-6-
independent pathways that exert a prosurvival eﬀect [220].
BMSCs stimulate MAPK signaling in myeloma cells through
IL-6R-independent mechanisms thereby circumventing the
need for Stat3-mediated signaling in response to IL-6 for
myelomacellsurvival.Chatterjeeetal.[220]wentontoshow
that disruption of both the IL-6R/Stat3 and MAPK signaling
pathways led to signiﬁcantly more apoptosis of MM cell lines
and primary MM cells even in the presence of BMSCs than
singly inhibiting each signaling pathway. These results sug-
gest that combined targeting of diﬀerent and independently14 PPAR Research
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Figure 3: PPARγ agonists inhibit Stat3-mediated IL-6 gene expression in myeloma cells. Inactivation of IL-6-activated Stat3 by PPARγ
agonists occurs in a PPARγ-dependent manner; however, the molecular mechanisms by which two distinct PPARγ agonists (15d-PGJ2
and troglitazone) suppress IL-6-activated Stat3 in MM cells diﬀer as shown in (a) [211]. Direct complex formation between phosphorylated
Stat3 and PPARγ activated by 15d-PGJ2 prevents Stat3 binding to its cognate response element (SBE) on the promoters of target genes ((a),
left). This mode of transcriptional inactivation does not require binding of the activated PPARγ transcription factor to DNA in the promoter
region and, thus, can occur in the absence of a PPRE. However troglitazone activated PPARγ promotes redistribution of the corepressor
SMRT from PPARγ to phosphorylated Stat3 so that Stat3 can no longer recruit the transcriptional machinery necessary for gene expression
((a), right) [211]. High levels of IL-6 are found in MM and promote myeloma cell proliferation and survival and indirectly promote tumor-
associated angiogenesis. The PPARγ agonists troglitazone and 15d-PGJ2 have been shown to inhibit transcription of the IL-6 promoter
driven by C/EBPβ and NF-κB[ 212]. Troglitazone-activated PPARγ binds to C/EBPβ preventing binding to its cognate response element
on the IL-6 promoter, which is the major mechanistic pathway of troglitazone-mediated downregulation of IL-6 expression. In addition
activated PPARγ competes with NF-κB for the PGC-1 coactivator, which leads to decreased NF-κB binding to the κB response element
on the IL-6 promoter contributing to inhibition of IL-6 gene expression, albeit to a lesser extent than inhibition of C/EBPβ ((b), left). A
slightly diﬀerent mechanistic emphasis on PPARγ-mediated inhibition of IL-6 gene expression occurs in response to 15d-PGJ2. Although
15d-PGJ2-activated PPARγ inhibits C/EBPβ-mediated transactivation of the IL-6 promoter similarly to troglitazone-activated PPARγ,t h e
predominant mode of inhibition is through 15d-PGJ2-activated PPARγ using the coactivator PGC-1 as a bridging protein to interact with
NF-κB to prevent transactivation of the IL-6 promoter. Furthermore, 15d-PGJ2 inactivates NF-κB by inhibiting phosphorylation of IKK and
IκB independently of PPARγ activation ((b), right). The schematics in this ﬁgure were adapted from [211, 212].PPAR Research 15
a c t i v a t e dp a t h w a y si sr e q u i r e dt oe ﬃciently induce apoptosis
of MM cells in the marrow microenvironment [220].
It should be kept in mind that anti-VEGF/VEGFR-
targeted therapy could occur through a number of mecha-
nistic pathways, such as direct inhibition of VEGF-induced
angiogenesis or indirectly through mechanisms that inhibit
expression of additional proangiogenic factors, promote
apoptosis, or induce tumor dormancy [88, 221]. Rather
than target the VEGF-signaling pathway, it may be possible
to alter the phenotype of the angiogenic endothelium.
The angiogenic EC phenotype is characterized by marked
downregulation of CD36/fatty acid translocase (FAT) [222].
CD36 is a glycoprotein associated with normal and patho-
logic processes including scavenger receptor functions, lipid
metabolism and fatty acid transport, cell adhesion, angio-
genesis, modulation of inﬂammation, activation of TGF-β,
atherosclerosis, diabetes, and cardiomyopathy [223]. PPARα
regulates expression of CD36 in mouse liver and PPARγ
regulates its expression in mouse adipose tissues [224,
225]. Furthermore, statins and PPARγ ligands together have
an additive eﬀe c to nu p r e g u l a t i o no fC D 3 6p r o d u c t i o n
by potentiating the transcription of the CD36 gene in
monocytes [226]. CD36 is the cellular receptor for TSP-1 on
microvascular endothelium and is necessary for its antian-
giogenic, proapoptotic activity, making CD36 an attractive
target for development of therapeutic agents [227].
Vascular endothelium expression of CD36 is sporadic
however, with lower levels of expression in larger vessels
[196, 228]. As discussed in Section 2.4, loss of endogenous
inhibitors of angiogenesis in favor of proangiogenic factors
produced by tumors leads to tumor-associated angiogenesis.
A small peptide (ABT510) derived from TSP-1 type 1 repeats
binds to CD36 and blocks tumorigenesis by reversing the
“angiogenic switch” [229]. Huang et al. [196] demonstrated
that 15d-PGJ2, troglitazone, and rosiglitazone potentiate the
antitumor activity of AB510 in a CD36-dependent manner.
Furthermore, these ligands upregulated EC expression of
PPARγ and CD36 [43, 196], which likely leads to the
synergistic inhibition of tumor-associated angiogenesis and
induction of EC apoptosis in vivo [196]. Importantly, lower
doses of PPARγ agonists could be used in combination with
AB510 to signiﬁcantly reduce tumor-associated angiogenesis
and promote EC apoptosis. This study provides compelling
evidence that PPARγ ligands could be useful as adjuvant or
combination therapy in treatment of tumor angiogenesis.
Another important molecular mechanism to target
for intervention of cancer progression in hematological
malignancies is regulation of stromal matrix remodeling
by proteases [193, 230]. PAI-1 production by ECs inhibits
plasmin-mediated proteolytic degradation of the ECM.
PPARγ ligands upregulate expression and release of PAI-1
from ECs [193], which would inhibit degradation of tumor-
associated ﬁbrin leading to EC migration, proliferation, and
angiogenesis [231]. PPARγ ligands inhibit the adhesion of
the myeloid leukemia HL-60 and K562 cells to the ECM as
well as their invasion through Matrigel [230]. In addition,
15d-PGJ2 and troglitazone in both the HL-60 and K562 cell
lines signiﬁcantly inhibited MMP-9 and MMP-2 expression
and proteolytic activities. The results of this study suggest
thatPPARγ ligandsmayinhibitleukemiccelladhesiontoand
invasionthroughtheECMaswellasregulateangiogenesisby
inhibiting matrix remodeling that favors cancer cell invasion
a n dE Cm i g r a t i o n[ 230].
2.9. MicroRNAs and PPARγ Agonists in Hematological Malig-
nancies. MicroRNAs (miRNAs) are short noncoding RNAs
that function as negative regulators of the stability and/or
translation of speciﬁc target mRNAs [232–234]. Typically,
miRNAs target a cluster of genes instead of one speciﬁc gene,
and a single miRNA can have more than 100 targets [233,
235]. Regulation of gene expression by miRNAs is increas-
ingly being accepted as a pivotal point in cell function, either
in normal development or disease states (recently reviewed
in [234, 236–238]). Mature miRNAs derive from primary
miRNAtranscriptsthatareeithertranscribedfromtheirown
promoter regions [239] or processed introns spliced from
pre-mRNAs[240].PrimarymiRNAsareﬁrstprocessedinthe
nucleus by the RNase III endonuclease, Drosha, to form pre-
miRNAs [241]. Pre-miRNAs are exported out of the nuclear
compartment into the cytoplasm by exportin-5 [242]. Once
in the cytoplasm, the pre-miRNA is further processed by
another RNase III endonuclease, Dicer [243]. Finally, the
mature miRNA is loaded onto the Argonaute (Ago) protein
and incorporated into the ribonucleoprotein complex, RISC
(RNA induced silencing complex) [244], which directs the
miRNA to its target mRNA. Mature miRNAs primarily bind
to transcripts through imperfect Watson-Crick base pairing
to conserved miRNA binding sites in the 3  untranslated
region (UTR) of target mRNAs [234, 245]. The ability of
miRNAs to regulate the expression of numerous genes at
once often leads to pleiotropic eﬀects and can modulate
multiple cellular pathways.
There is growing evidence that dysfunctional expression
of miRNAs is a common feature of malignancy in general
and hematological malignancy in particular [233, 246].
Aberrant miRNAs have been documented in almost all
hematological malignancies [247]. For example, Calin and
colleagues [248] ﬁrst implicated miRNAs in hematological
malignancies when they demonstrated that miR-15 and
miR-16 are frequently deleted or downregulated in CLL
associated with deletions on chromosome 13q14. Deletion
or downregulated expression of miR-15a and miR-16 on
chromosome 13 is also found in MM cells [249]; deletion
of chromosome 13 predicts signiﬁcantly reduced survival in
patients with MM [250]. In 2005, another group reported
that the polycistronic precursor transcript of the miR-
17∼92 cluster, which encodes seven diﬀerent miRNAs, is
overexpressed in human B cell lymphomas and acts as
an oncogene [251]. The miR-17∼92 cluster is ampliﬁed
and/or overexpressed in other hematological malignancies
including AML [252, 253]a n dM M[ 246], as well as
cancers of epithelial origin such as lung [254], thyroid
[255], and hepatocellular [256] carcinomas. Overexpression
of miR-21 occurs in MM [246, 257] and other cancers
including glioblastoma [258] and breast cancer [259]. Thus,
there is enormous hope that miRNA research will provide
breakthroughs in the understanding of cancer pathogenesis
and in the development of new prognostic markers [260].16 PPAR Research
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the HIF-1α subunit of the transcription factor, HIF-1, is constitutively produced and rapidly degraded by pVHL-induced proteasomal
degradation, which prevents transcription of the VEGF gene. In solid tumors, HIF-1-induced VEGF expression occurs when tumor growth
exceeds the dimensions where existing blood vessels can feed the tumor and carry away waste products. The resulting hypoxia leads to
stabilization of HIF-1α and activation of the HIF-1 heterodimer resulting in high VEGF production by tumor cells. Although solid tumors
do not develop in hematological malignancies, angiogenesis is an important process of disease progression. CLL B cells constitutively express
high levels of VEGF and VEGFRs leading to autocrine signaling and increased resistance to apoptosis. Recently, Ghosh et al. [273] discovered
that HIF-1 is stabilized in CLL B cells due to low levels of pVHL as a result of miR-92-1 overexpression and subsequent repression of
translation of the VHL transcript. Therefore, HIF-1 accumulates and translocates to the nucleus where it forms an active complex with the
transcriptional coactivator p300 and phosphorylated Stat3 and, together with the basal transcription machinery, transactivates the VEGF
promoter. PPARγ agonists could potentially inhibit overexpression of VEGF by inhibiting Stat3 signaling in CLL B cells. The schematic in
this ﬁgure was adapted from [273].
Kuehbacher et al. [261] recently reviewed miRNAs that
possess proangiogenic or antiangiogenic function. The miR-
17∼92 cluster, let-7f, and miR-27b posses proangiogenic
functions, in part, by inhibiting expression of TSP-1 and
CTGF. A role for miR-221 and miR-222 in blocking angio-
genesis is suggested by their ability to inhibit EC migration,
proliferation, and angiogenesis in vitro. In addition, miR-
21 is implicated in the invasive and metastatic properties of
colonandbreastcancercelllinesbytargetingmultipletumor
suppressor genes, such as PTEN, TPM1, and MASPIN [259,
262, 263]. Moreover, miR-21 overexpression, which occurs
in MM as discussed below, is associated with advanced
clinical disease, lymph node metastasis and poor prognosis
for overall survival in breast cancer [264]. The Sessa group
demonstrated that a functional miRNA biogenesis pathway
is required for angiogenesis [265, 266]. Inactivation of
Dicer, the miRNA processing enzyme, impairs angiogenesis
induced by multiple stimuli such as VEGF, and during
tumorigenesis and wound healing [266]. VEGF also induces
the expression of several proangiogenic miRNAs includ-
ing the miR-17∼92 cluster [266]. Furthermore, miR-130a
functions in angiogenesis by inhibiting expression of two
antiangiogenic homeobox transcription factors,HOXA5 and
GAX [267].
Although the mechanisms regulating expression of
miRNAs are only beginning to be understood [234, 236–
238, 268, 269], key regulators of the biosynthetic pathway are
often abnormally expressed in hematological malignancies
[270]. Recently, L¨ oﬄer and colleagues [257] demonstrated
that survival of IL-6-dependent MM cells involves Stat3-
mediated induction of miR-21. Two bona ﬁde IL-6 type II-
response elements for Stat3 binding are located upstream
of the miR-21 genes of various vertebrate species [257].
Stat3regulatestransactivationofseveralanti-apoptoticgenes
such as survivin, Bcl-2, and Mcl-1. L¨ oﬄer et al. [257]
suggest that Stat3 induction of miR-21 represents a “slow-
acting yet long-lasting” survival stimulus to complement the
immediate induction of anti-apoptotic proteins. The cancers
in which miR-21 is overexpressed contain constitutively
activated Stat3 for survival or growth [257]. These results
suggest that miR-21 is important for the oncogenic potential
of Stat3 in the pathogenesis of MM and other malignancies.PPAR Research 17
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Figure 5: PPARγ is broadly expressed in the eye providing a pharmacological target for treating ocular angiogenesis. PPARγ expression is found
intheretinaincludingRPEcells,REC,pericytes[287],andganglioncells.Inthecornea,PPARγ ismostprominentlylocalizedintheepithelial
and endothelial layers. Excessive angiogenesis is a pathological hallmark of a number of eye diseases, and anti-VEGF/VEGFR strategies are
used therapeutically to treat ocular neovascularization. Manifestations of hematological malignancies in the eye have been documented for
leukemia, lymphoma, and multiple myeloma. The potential beneﬁts of PPARγ agonist therapy to inhibit tumor-associated angiogenesis
could also be applied to treatment of neovascular eye diseases.
IL-6-mediated activation of Stat3 is also important for
transformation of nonmalignant breast epithelial cells to
self-renewing mammospheres that contain CSCs [271].
Inﬂammation in cancer leads to elevated IL-6 production by
two mechanisms: Src-mediated activation of NF-κB leading
to transactivation of the IL-6 gene, and rapid degradation of
let-7 miRNA, which is a direct inhibitor of IL-6 expression
[271]. Let-7 is downregulated in some cancers including
Burkitt lymphoma [272] thereby leading to elevated IL-6
production, likely due to activation of the oncogenic NF-κB-
IL-6-Stat3 inﬂammatory pathway. In that the PPARγ agonist
CDDO-Me inactivates Src and Stat3 in cancer cells [215],
further investigation of the eﬃcacy of various PPARγ ligands
as anticancer agents is certainly warranted.
Recently, Roccaro and colleagues [249] identiﬁed a mul-
tiple myeloma-speciﬁc miRNA signature characterized by
downexpression of miR-15a and miR-16 and overexpression
of miR-222, miR-221, miR-382, miR-181a, and miR-181b
in bone marrow-derived CD138+ MM cells. Both miR-15a
and miR-16 regulate proliferation and growth of plasma
cells by inhibiting Akt and MAPK cell survival signaling
pathways. However, both miR-15a and miR-16 are deleted
on chromosome 13 associated with MM [249] thereby pre-
venting normal repression of cell proliferation during cancer
progression. Pichiorri et al. [246] also identiﬁed an miRNA
signature associated with MM pathogenesis. Overexpression
of miR-21, the miR-106b∼25 cluster, and miR-181a and
miR-181b was found in MM and monoclonal gammopathy
ofundeterminedsigniﬁcance(MGUS)samples.Ontheother
hand, selective upregulation of miR-32 and the miR-17∼92
cluster was identiﬁed only in MM cells. Expression of sup-
pressor of cytokine signaling (SOCS)-1, involved in negative
feedback regulation of Jak/Stat signaling, is downregulated
by miR-19a and miR-19b thereby leading to sustained IL-
6-mediated MM cell proliferation [246]. Furthermore, miR-
19a,miR-19b,miR-181a,andmiR-181bantagonistssuppress
human MM tumor cell growth in nude mice, suggesting that
miRNAs that modulate the expression of proteins critical
to myeloma pathogenesis, including the IL-6-regulated Stat3
pathway, are potential targets for development of new
therapeutic strategies for treatment [246].
The Stat3-regulated gene, HIF-1α, is constitutively
expressed under normoxia in CLL B cells, most likely as a
result of low production of pVHL, which is responsible for
HIF-1α degradation. Ghosh and colleagues [273]d e m o n -
strated that overexpression of miR-92 in CLL B cells targets
the VHL transcript to repress its translation (Figure 4).
Furthermore, stabilized HIF-1α forms an active complex18 PPAR Research
with the transcriptional coactivator p300 and activated Stat3
on the VEGF promoter, which likely explains the anomalous
autocrine VEGF secretion from CLL B cells [273]. In that
PPARγ agonists inhibit the IL-6-regulated Stat3 signaling
cascade, a role for PPARγ agonists in regulating expression
of miRNAs critical to the pathogenesis of hematological
malignanciesmaybeanimportantavenueoffuturescientiﬁc
investigations.
Recently, miRNAs have emerged as epigenetic regulators
of metabolism and energy homeostasis [274]. It is clear that
there is an obesity epidemic in the United States [275].
Increased body weight is associated with increased mortality
for most all types of cancers including hematological malig-
nancies[276].Additionalstudieshaveconﬁrmedthatobesity
puts patients at a moderate increased risk of developing MM
[276–279], and that this risk may be higher in women than
men [279]. An important link between obesity and MM is
elevated expression of IL-6 in adipose tissue [280] and bone
marrow [207], which also leads to elevations in circulating
I L - 6 .L i ne ta l .[ 274] demonstrated that the miR-27 gene
family is downregulated during adipogenic diﬀerentiation.
Furthermore, overexpression of miR-27 speciﬁcally inhibits
adipocyte formation and expression of PPARγ and C/EBPα,
the two master transcriptional regulators of adipogenesis.
Although PPARγ and C/EBPα mRNA and protein levels
were markedly reduced by miR-27a or miR-27b, it was
not a direct miRNA eﬀect [274]. Expression of miR-27 is
increased in fat tissue of obese mice and is regulated by
hypoxia, an important extracellular stress associated with
both obesity and cancer. During adipogenesis the expression
of miR-27b, an important regulator of angiogenesis, is
downregulated in human adipogenic stem cells, and PPARγ
mRNA expression increases concomitantly with decreasing
miR-27b expression [281]. Both miR-27a and miR-27b
directly bind RXRα mRNA and regulate RXRα translation in
rat hepatic stellate cells [282]. It is well known that RXRα
heterodimerizes with PPARγ to activate numerous genes
requiredforadipogenesisandenergymetabolism.Thesedata
suggest that miR-27 represents a new class of adipogenic
inhibitors and their downregulation may play a role in the
pathological development of obesity [274]. Furthermore, in
that PPARγ is a master regulator of adipogenesis and target
of insulin sensitizing drugs, it is reasonable to consider that
the beneﬁcial eﬀects of PPARγ agonists in cancer treatment
may be exerted through regulation of energy homeostasis, at
least in part, by modulation of miRNA expression. Indeed,
theanticarcinogenicactivityofoneofthetriterpenoidsisdue
to repression of oncogenic miR-27a [283].
All known forms of the human PPARγ mRNA contain
numerous miRNA binding sites in the 3 UTR as predicted
through diﬀerent bioinformatic algorithm databases (Tar-
getScan [284], miRanda [285], PicTar [286]). The miRNA
binding sites for miR-27a/b, miR-130a/b, miR-301, miR-
34a/b in the PPARγ 3 UTR are conserved in human, chimp,
mouse, and rat. Notably, two conserved binding sites for
miRNAs in the PPARγ 3 U T Ra r ef o rm i R - 2 7 ba n dm i R -
130athathaveangiogenicorproliferativefunctions.Itwould
be interesting to determine whether these miRNAs suppress
PPARγ function during angiogenesis and/or tumor growth.
This could lead to identiﬁcation of novel targets that may
induce PPARγ expression leading to the anticancer functions
of cell diﬀerentiation and loss of proliferation. However,
ar o l ef o rP P A R γ agonists in miRNA-based therapeutic
strategies to treat cancer awaits further clariﬁcation by new
research endeavors.
3. Anticancer Role of PPARγ Agonists as
Adjuvantor Combination Therapy in
Hematological Malignanciesof the Eyes
3.1. Ocular Hematological Malignancy. Ocular lymphoma is
relatively uncommon, accounting for 5–10% of all extran-
odal lymphomas [288]. However, it is one of the most com-
mon orbital malignancies and it is increasing in incidence
because of its association with the acquired immunodeﬁ-
ciency syndrome (AIDS) [289]. Ocular lymphoma can be
divided into intraocular and adnexal disorders, the former,
including malignant lymphoid cells, invade the retina, vitre-
ous body, or optic nerve head; the latter include conditions
aﬀecting the eyelid, the conjunctiva, the lacrimal gland, and
the orbit [290]. Primary intraocular lymphoma (PIOL) is
a subset of primary central nervous system lymphoma. It
is usually a large B-cell NHL [291]. PIOL typically presents
as a vitritis that is unresponsive to corticosteroid therapy.
Diagnosis of PIOL requires pathologic conﬁrmation of
malignant cells in specimens of the cerebrospinal ﬂuid, vitre-
ous, or chorioretinal biopsies. The extranodal marginal zone
lymphoma (mucosaassociated lymphoid tissue lymphoma)
is the dominant lymphoma subtype in the orbit and ocular
adnexa. Extranodal marginal zone lymphoma is considered
to be the neoplastic counterpart of the marginal zone cells
in reactive follicles [292]. Although optimal therapy has yet
to be determined [293], it is believed that PIOL should be
treated with a combination of chemotherapy and radiation.
Ocular involvement is common in patients with acute
leukemia and has been described in up to half of patients at
the time of diagnosis [294]. Eye involvement may be due to
leukemic inﬁltration of various ocular tissues or as a result
of one of the secondary complications of the disease [295].
These complications include anemia, thrombocytopenia,
and leukostasis, which can lead to retinal hemorrhaging and
ischemia [294]. Hemorrhaging in the retina is the most
striking feature of ocular leukemia. Furthermore, retinal
microaneurysms, capillary closure, and neovascularization
have been documented in individuals with chronic leukemia
[296, 297]. The treatments include chemotherapy, radi-
ation, or bone marrow transplantation. Ocular ﬁndings
may be the ﬁrst manifestation of MM [298]. It may also
occur as one of the extramedullary manifestations of the
disease or as the ﬁrst sign of insuﬃcient chemotherapy.
MM causes ocular pathology by direct inﬁltration or as
extramedullaryplasmacytomasresulting in the displacement
or compression of tissues causing hyperviscosity syndrome
andimmunoglobulinlightchaindepositioninoculartissues.
Virtually any ocular structure can be aﬀected, including the
conjunctiva, cornea, sclera, lens, retina, optic nerve, lacrimal
glands, and orbit [298]( Figure 5).PPAR Research 19
3.2. Ocular Neovascularization. Ocular angiogenesis or ocu-
lar neovascularization, the abnormal growth of blood vessels
in the eye, is the hallmark of the vast majority of eye diseases
that cause a catastrophic loss of vision including diabetic
retinopathy, AMD, retinopathy of prematurity, and vein
occlusion retinopathy [299, 300]. The new vessels may grow
into nearly all mature ocular tissue and aﬀect the cornea, iris,
retina, and optic disk [301]. They are structurally weak, both
leaking ﬂuid and lacking structural integrity. Moreover, the
resultant hemorrhage, exudate, and accompanying ﬁbrosis
often cause blindness [302].
The cornea is a highly organized transparent tissue
located in the anterior part of the eye and it is normally
avascular.However,undercertainconditions,suchascorneal
trauma, chemical burns, infection, and inﬂammation, the
development of new blood vessels starts from the vessel
of the limbal area (Figure 5). Newly formed blood vessels
cover the corneal surface [303], which can lead to severe
or permanent visual impairment [302]. The choroid is
the layer of blood vessels and connective tissue between
the sclera and retina and supplies nutrients to the inner
parts of the eye [304]. Choroidal neovascularization (CNV)
is associated with many other conditions, such as AMD,
inﬂammatory, infectious, degenerative, hereditary, congeni-
taldisorders,tumors,trauma,andafewmiscellaneousocular
disorders[302].InCNV,neovascularchannelsgrowfromthe
choroidal vasculature and extend into the subretinal space
leading to local tissue damage. Activation and migration of
choroidal ECs (CECs) and retinal pigment epithelial (RPE)
cells into the CNV membranes play an important role in
the development of the lesion [305]. The mammalian retina
is a light sensitive tissue lining the inner surface of the
eye, which is composed of multiple cell-types organized
within deﬁned layers. It has a dual blood supply from the
centralretinalarteryandthechoroidalbloodvascularsystem
[304]. Neovascularization of the retina is a critical part of
the disease process associated with retinopathy in diabetes,
prematurity, and sickle cell disease [302].
3.3. Expression of PPARγ in the Eye and Eﬀects on Ocular Neo-
vascularization. PPARγ expression in the mammalian eye
has been reported prominently in retina [306, 307] including
RPE cells [194, 308, 309], retinal capillary ECs (REC) [310,
311], retinal pericytes [287], and retinal ganglion cells [312].
PPARγ is most prominently localized in the epithelial and
endothelial layersofthecornea[198].PPARγ is alsofoundin
CECs [194] and in orbital ﬁbroblasts [313, 314]. The broad
expression of PPARγ in the eye provides a pharmacological
target for treating ocular angiogenesis.
In vivo alkali-burned mouse cornea experiments showed
thatneovascularizationandscarformationaresuppressedby
introduction of PPARγ gene expression. PPARγ overexpres-
sion suppressed monocyte/macrophage invasion and sup-
pressedthegenerationofmyoﬁbroblasts,aswellasupregula-
tion of inﬂammation/scarring-related growth factors (TGF-
β, CTGF, and VEGF) and MMPs in a healing cornea. In
vitroexperimentsshowedthatoverexpressionofPPARγ sup-
pressed epithelial cell expression of MMP-2/-9 and TGF-β1,
inhibited cell migration, and suppressed myoﬁbroblast gen-
e r a t i o nu p o ne x p o s u r et oT G F - β1. Thus, adenoviral-driven
expression of the PPARγ gene led to inhibition of the anti-
inﬂammatory and antiﬁbrogenic responses induced in an
alkali-burned mouse cornea, and also inhibited activation of
ocular ﬁbroblasts and macrophages in vitro [12]. In a VEGF-
induced neovascular rat cornea model, intrastromal implan-
tation of the PPARγ ligands pioglitazone [198] or 15d-PGJ2
[22] resulted in decreasing MVD, indicating inhibition of
ocular angiogenesis. Furthermore, systemic oral administra-
tion of rosiglitazone and troglitazone signiﬁcantly inhibits
vessel growth in a dose-dependent fashion in a model of
FGF-2-induced mouse corneal neovascularization [195].
PPARγ ligands troglitazone and rosiglitazone inhibit
VEGF-induced cell proliferation and migration in bovine
CECs and human RPE cells in vitro. Troglitazone also
inhibits VEGF-induced tube formation (neovascularization)
of CECs [194]. Troglitazone pretreatment can signiﬁcantly
prevent TGF-β-induced epithelial-mesenchymal transition
of human RPE cells, and retard cell migration [315]. In
vivo, laser photocoagulation induced CNV was markedly
inhibited by intravitreal injection of troglitazone in rat
and monkey eyes. The lesions showed signiﬁcantly less
ﬂuorescein leakage and were histologically thinner in the
troglitazone-treatedanimalswithoutapparentadverseeﬀects
in the adjacent retina or in control eyes [194], indicating that
thePPARγ ligandsarelogicalfortherapytosuppressvascular
permeability in the eye.
PPARγ agonists,troglitazone,rosiglitazone,Pioglitazone,
RWJ241947, and 15d-PGJ2, inhibit proliferation of human
REC and pericytes in vitro through a PPARγ-independent
pathway [316]. TZDs downregulate cyclin E (S-phase cyclin)
andcyclinA(G2/M-phasecyclin)resultingincellcyclearrest
[316]. Troglitazone and rosiglitazone inhibit VEGF-induced
proliferation and tube formation by bovine REC in collagen
gels, and inhibit VEGF-induced REC migration in a dose-
dependent manner [311]. Retinal angiogenesis is induced
in newborn mice by oxygen-induced ischemic injury; how-
ever, intravitreal injection of troglitazone or rosiglitazone
markedly reduced development of retinal neovascular tissue
[311]. In the chick chorioallantoic membrane model of
angiogenesis, pioglitazone and rosiglitazone signiﬁcantly
inhibit EC migration as well as the proangiogenic eﬀects of
FGF-2 and VEGF [27]. Rosiglitazone may delay the onset
of proliferative diabetic retinopathy, possibly because of its
antiangiogenic activity [317].
Taken together, these studies demonstrate that PPARγ
ligands are potent inhibitors of angiogenesis in vivo and
in vitro, and suggest that PPARγ may be an important
molecular target for inhibiting angiogenesis. The use of
PPARγ ligands to prevent pathological angiogenesis holds
great potential as a novel therapeutic for neovascularized
eye diseases. It may also apply to other neovascularization-
related diseases, including hematological malignancies of the
eye. However, future clinical investigations should consider
analysis of the potential beneﬁts of PPARγ agonist treatment
along with ongoing evaluation of potential cardiac risk in
studies where the risk-beneﬁt proﬁles are deemed appropri-
ate [317].20 PPAR Research
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Figure 6:DirectandindirecteﬀectsofPPARγ agonistsontumorandstromalcells.“Oﬀ-target”(PPARγ-independent)eﬀectsofPPARγ agonists
frequently occur when the agonists are used at high concentrations (much higher than needed to active PPARγ by ligand binding) and in
responsetoelectrophilicPPARγ agonistssuchas15d-PGJ2 andCDDO,whichcanpromotecovalentbondformationwithcellularproteinsin
a redox-sensitive manner to modulate signal transduction pathways. PPARγ agonists have been shown to aﬀe c ta l m o s te v e r ys t a g eo ft u m o r
progression from inhibition of uncontrolled tumor growth, induction of apoptosis, inhibition of tumor cell adhesion and invasion through
stromal compartments into or out of the blood stream, and inhibition of tumor-associated angiogenesis. PPARγ agonists induce expression
of tumor-inhibiting molecules such as CD36, the EC receptor for TSP-1, as well as promote the diﬀerentiation of tumor cells, which tends
to reduce their invasive and metastatic capabilities. The schematic in this ﬁgure was adapted from [181].
4. The Paradox of PPARγ asaMolecular
Target in Anticancer Therapy
The aforementioned studies examining the role of PPARγ
ligands for treatment of hematological, ocular, and solid
malignancies is by no means a complete review of the
available literature. The list of oﬀ-target eﬀects of PPARγ
agonists continues to grow [51]. Furthermore, many of
the published studies suggesting that PPARγ ligands exert
antitumor properties did not determine whether the eﬀects
required ligand activation of the PPARγ transcription factor
per se (Table 3). Many human cancer cell lines express high
levels of PPARγ, which when treated with high concen-
trations of TZDs, undergo cell cycle arrest, apoptosis, or
diﬀerentiation, suggesting a link between PPARγ signal-
ing and their antitumor activities. In contrast, mounting
evidence refutes the dependence of the antitumor eﬀects
of TZDs on PPARγ activation [25, 51, 318]. Of note,
the oﬀ-target eﬀects of PPARγ ligands usually occur at
much higher concentrations than those required for ligand-
dependentPPARγeﬀects,andthereisnocorrelationbetween
the expression levels of PPARγ in cancer cells and their
sensitivity to TZDs [25, 51, 318]. Indeed, PPARγ agonists
exert pleiotropic eﬀects on signal transduction pathways
involved in cell proliferation, survival and diﬀerentiation
[25, 51, 71, 188, 318–322]( Table 3 and Figure 6).
Currently, two PPARγ agonists belonging to the TZDs
remain on the market, rosiglitazone (Avandia) and pioglita-
zone (Actos). In 2000, troglitazone (Resulin) was removed
from the market due to severe hepatotoxicity. Moreover,
the incidence of delayed drug-induced liver injury that pro-
gresses after discontinuation of drug therapy, and whether
such injury is speciﬁc to just troglitazone or TZDs as a
class of drugs, remains unknown [323]. Additional adverse
eﬀects associated with TZDs used for insulin sensitizing
therapy include edema, weight gain, macular edema, and
heart failure [323, 324]. TZDs may cause hypoglycemia
when combined with other antidiabetic drugs as well as
decrease hematocrit and hemoglobin levels. Furthermore,
an increased risk of bone fracture is linked to TZD therapy
[324, 325]. When considering the use of PPARγ agonists as
adjuvant or combination therapy in hematological malig-
nancies,itwillbeimportanttodesignappropriatepreclinical
studies that assess the severity of these side eﬀects in the
context of each type of cancer. For example, increased
edema is associated with increased vascular permeability.
The loss of endothelial barrier integrity leads to increased
vascular permeability, enhanced transendothelial migration,
andmetastaticspreadofcancercells[75].Thus,thepotential
for TZDs to promote rather than prevent the metastatic
spread of cancer should be considered. The malignant
proliferation of plasma cells in MM produces skeletal lesionsPPAR Research 21
leading to bone pain and pathologic fractures such as
vertebral compressions [326]. In that TZDs are associated
with increased risk of bone fractures; the use of TZDs for
treatment of MM must be evaluated as well.
Evidence suggesting that the eﬀects of TZDs on improv-
ing endothelial-dependent vascular function and decreas-
ing inﬂammatory biomarkers independently of insulin-
sensitizing eﬀects came from studies reporting the eﬀects
of TZDs in diabetic and nondiabetic individuals with
atherosclerosis[327–329].Ingeneral,PPARγ agonistsinhibit
tumor-associated angiogenesis by inhibiting FGF-2- and
VEGF-induced EC growth, invasion and migration in vitro
and in vivo [27, 192], downregulate expression of VEGF
by tumor cells [195, 199] and VEGFRs by EC [32], and
decrease tumor-associated MVD [24, 32, 198]a n dE Ct u b e
formation [202], measures of angiogenesis in vivo and in
vitro, respectively. TZDs inhibit pathological angiogenesis
associated with diabetic retinopathy [287, 317], as well as
choroidal and retinal neovascularization [194, 198, 311], and
suppress primary tumor growth and metastasis by inhibiting
angiogenesis [35]( Table 3). Interestingly, in contrast to these
reports, TZDs increase VEGF expression in human vascular
smooth muscle cells [330] and promote angiogenesis after
ischemia [331]. Additional reports suggest that PPARγ
ligands are capable of promoting angiogenesis by inducing
VEGF expression [28, 30, 203].
Huang and colleagues [30] have suggested that pioglita-
zone has diﬀerent eﬀects on pathological angiogenesis com-
pared to ischemia-induced collateral vessel growth [332].
TZDs promote diﬀerentiation of EPCs/APCs towards the
endothelial lineage [197, 200, 201], consistent with the idea
that PPARγ ligands have diﬀerential eﬀects on angiogenesis
needed for restoration of homeostasis in cardiovascular
disease or diabetes compared to pathological angiogenesis
associated with cancer progression. The role of PPARγ and
its ligands in inhibiting or promoting angiogenesis is likely
context dependent (Section 2.7 and Table 3)[ 30, 332]; thus,
the use of PPARγ ligands alone or in addition to antian-
giogenic agents for treatment of hematological malignancies
will require a better understanding of the eﬀects of PPARγ
agonists on EC function during pathological angiogenesis.
Many studies have demonstrated beneﬁcial eﬀects of
PPARγ agonists on atherosclerosis and ischemia reperfusion
injury by reducing inﬂammation, preventing restenosis after
percutaneous coronary intervention, and in some instances,
preventing myocardial infarction and cardiovascular death.
Recently,however,anumberofreviewarticleshavediscussed
the“rosiglitazonedebate”aboutwhethertakingrosiglitazone
puts patients at a higher overall risk of cardiovascular death.
The higher risk is based on ﬁndings derived from meta-
analyses of existing clinical trial data, the release of FDA
safety warnings that rosiglitazone increases cardiac ischemic
risk, manufacturer updates on TZD labels with a black-
box warning for heart failure, as well as warnings and
precautions about coadministration of rosiglitazone with
nitrate or insulin [333–336]. TZDs are known to induce salt
and water retention, which exacerbate the risk of congestive
heart failure in patients with type 2 diabetes. Rosiglitazone
is a more potent agonist of PPARγ than pioglitazone, thus
increased ﬂuid retention and salt imbalance may explain the
higher risk of heart failure with this TZD [336]. However,
even though treatment with rosiglitazone may, in general, be
associated with a higher incidence of cardiovascular events,
some studies suggest that there is no increase in all-cause
or cardiovascular mortality observed with rosiglitazone
treatment [333, 335]. Clearly, prospective randomized trials
needtoincludeoutcomesmeasurestodeterminewhetherthe
TZDs and other such compounds under development put
patients at a higher overall risk of cardiovascular death.
As cancer treatments improve, the number of patients
who reach the 5-year benchmark of disease-free survival
continues to grow. However, adverse eﬀects of anticancer
therapy may confound long-term survival. For example, as
methods for detecting and treating breast cancer improve,
survival of breast cancer patients is increasing but the side
eﬀects of adjuvant therapy, including cardiotoxicity, remain
clinically important [337]. Agents commonly used for the
treatment of breast cancer, including anthracyclines and
trastuzumab, have been associated with cardiotoxicity [338],
which ranges from subclinical to life-threatening pathology
and even fatal results [339]. Imatinib (Gleevec) inhibits the
continuously active tyrosine kinase, Bcr-Abl, which results
from the translocation of chromosomes 9 and 22 and is
eﬀective for the treatment of CML as well as ALL; however,
cardiotoxicity is a potentially serious side eﬀect of this drug
as well [340]. In that the TZD class of PPARγ agonists
is associated with adverse cardiovascular events, additional
studies on the eﬃcacy of PPARγ agonists and other lead
compounds as adjuvant or combination therapy to treat
cancer should be designed to look at the cardiovascular risks
and beneﬁts in addition to their eﬃcacy in treating the
primary disease.
5. Conclusions
The goal to ﬁnd a cure for all types of cancer is a major ini-
tiative of both public and private grant funding institutions
and foundations. Thus, forwarding thinking researchers are
exploring strategies to identify molecular expression proﬁles
of cancer subtypes and CSCs, to optimize tumor imaging
methods to identify cancer micrometastases, as well as to
develop more-speciﬁc, less toxic drugs through medicinal
chemistrytoprovidetailoredtherapytotreatandcurecancer
in individual patients. However, metastatic disease remains
the major cause of morbidity and mortality in both solid
tumors and hematological malignancies. Because tumor-
associated angiogenesis is critical for cancer progression and
metastatic disease, the initiative to identify molecular targets
and new or improved chemotherapeutic or biologic agents
to inhibit angiogenesis is a high priority area of research in
cancer medicine.
Speciﬁc areas of research where PPARγ agonists may be
further examined for eﬃcacy in treatment of angiogenesis
in hematological malignancies as well as comorbidities that
aﬀect quality of life for long-term cancer survivors include
signal transduction pathways (e.g., Jak/Stat, PI3K/Akt,
PTEN, mTOR) [181, 341, 342], aberrant/oncogenic
miRNAs [246, 257, 261, 283, 343–345], targeting CSCs while22 PPAR Research
sparing normal hematopoietic stem cells, and correcting
dysregulated metabolic pathways due to drug side eﬀects
such as hyperglycemia, hypertension, gastrointestinal
toxicity, coagulation disorders, and depression associated
withtheneurotoxicity ofchemotherapeuticdrugs[341,346–
348]. Moreover, limitations in the experimental design of
published studies should be carefully evaluated. A signiﬁcant
number of studies continue to use troglitazone as a
PPARγ agonist despite its having been pulled from the
marketplace due to hepatotoxicity. In vitro experiments
examining the eﬃcacies of candidate drugs as inhibitors of
angiogenesis need to reﬂect the complexity of the tumor
microenvironment in keeping with the in vivo context.
For example, large vessel ECs isolated from the veins of
human umbilical cords (HUVECs) are frequently used to
study angiogenesis by capillary tube formation in 2D-matrix
conﬁgurations in vitro; however, in vivo tumor-associated
angiogenesis occurs in a complex environment composed
of multiple cell types including microvessel ECs and matrix
constituents in a 3D-conﬁguration. It will also be important
to determine whether the therapeutic eﬀects of PPARγ
agonists are due to oﬀ-target interactions. In conclusion, we
hope that this paper has provided a conceptual framework
upon which future studies will be designed to unravel the
pleiotropic eﬀects of PPARγ in the context of the stromal
microenvironment during tumor angiogenesis, growth and
metastasis in hematological malignancies.
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